. . "La inmunoterapia, bioterapia, terapia biol\u00F3gica, terapia modificadora de la respuesta biol\u00F3gica o terapia MRB, en medicina, se refiere al conjunto de estrategias de tratamiento para estimular o reponer el sistema inmunitario frente al c\u00E1ncer, infecciones u otras enfermedades as\u00ED como para aminorar los efectos secundarios de tratamientos muy agresivos usados contra el c\u00E1ncer. El objetivo puede ser profil\u00E1ctico (preventivo) o terap\u00E9utico (curativo o de mantenimiento). Dentro de los tratamientos biol\u00F3gicos est\u00E1n los anticuerpos monoclonales, las vacunas y los denominados factores de crecimiento.\u200B"@es . . . . . "Biologick\u00E1 l\u00E9\u010Dba nebo imunoterapie, \u0159\u00EDd\u010D. c\u00EDlen\u00E1 l\u00E9\u010Dba, vyu\u017E\u00EDv\u00E1 imunitu organismu a jej\u00ED zeslaben\u00ED nebo zes\u00EDlen\u00ED k l\u00E9\u010Db\u011B nemoc\u00ED. Imunoefektorov\u00E9 bu\u0148ky typu lymfocyt\u016F, makrof\u00E1g\u016F, dendritick\u00FDch bun\u011Bk,NK bu\u0148ky, T-lymfocyty mohou \u00FA\u010Dinn\u011B bojovat proti rakovin\u011B \u010Di n\u011Bkter\u00FDm autoimunitn\u00EDm chorob\u00E1m d\u00EDky tomu, \u017Ee jsou l\u00E9pe zn\u00E1m\u00E9 struktury a pochody na povrchu i uvnit\u0159 bu\u0148ky. Terapie granulocyte colony-stimulating factor (G-CSF), interferon\u016F, imikvimod\u016F a bun\u011B\u010Dn\u00E9 membr\u00E1nov\u00E9 frakce bakteri\u00ED jsou povoleny pro medic\u00EDnsk\u00E9 pou\u017Eit\u00ED. Dal\u0161\u00ED typy terapi\u00ED IL-2, IL-7, IL-12, chemokiny, (CpG) oligodeoxynukleotidy a glukany proch\u00E1zej\u00ED klinick\u00FDm hodnocen\u00EDm."@cs . . . . . "Immunoterapia edo terapia biologikoa tratamendu mediku mota bat da, immunitate-sistemaren aktibazioan datzana minbiziari -bereziki- eta beste gaixotasun batzuei (gaitz autoimmuneak, endekapen-gaitzak...) aurre egiteko. Terapia honetan erabiltzen diren substantzien artean antigorputz monoklonalak, txertoak eta interferoia, besteak beste, daude. Kimioterapia klasikoaren aldean, immunoterapiak gorputzak berak ekoizten dituen substantziak erabiltzen ditu agente terapeutiko gisa. Hortik datorkio terapia biologikoaren izena. Immunoterapia profilaktikoa edo terapeutikoa izan daiteke."@eu . . . . "Immunoterapi \u00E4r behandling av sjukdom med immunologiska metoder."@sv . . . . . . . . . . "50730"^^ . "Immuntherapien sind Behandlungsformen, bei denen das Immunsystem beeinflusst wird. Hierbei kommen in Abh\u00E4ngigkeit von der Erkrankung modulierende (stimulierende und supprimierende) oder substituierende (ersetzende) Verfahren zur Anwendung."@de . . "\u514D\u75AB\u7642\u6CD5\uFF08\u3081\u3093\u3048\u304D\u308A\u3087\u3046\u307B\u3046\u3001\u82F1: Immunotherapy\uFF09\u306F\u3001\u300C\u514D\u75AB\u5FDC\u7B54\u3092\u8A98\u5C0E\u3001\u5897\u5F37\u3001\u307E\u305F\u306F\u6291\u5236\u3059\u308B\u3053\u3068\u306B\u3088\u308B\u75BE\u60A3\u306E\u6CBB\u7642\u300D\u3067\u3042\u308B\u3002\u514D\u75AB\u7642\u6CD5\u306F\u3001\u514D\u75AB\u5FDC\u7B54\u3092\u8A98\u767A\u307E\u305F\u306F\u5897\u5E45\u3059\u308B\u514D\u75AB\u7642\u6CD5\u3001\u514D\u75AB\u5FDC\u7B54\u3092\u6291\u5236\u3059\u308B\u514D\u75AB\u7642\u6CD5\u306B\u5206\u985E\u3067\u304D\u308B\u3002 \u514D\u75AB\u7642\u6CD5\u306B\u4F7F\u3046\u85AC\u306F\u3001\u75C5\u539F\u4F53\u306B\u3088\u308B\u611F\u67D3\u3092\u6CBB\u7642\u3059\u308B\u969B\u306B\u4F7F\u7528\u3057\u3066\u3082\u3001\u75C5\u539F\u4F53\u304C\u8010\u6027\u3092\u5F97\u308B\u53EF\u80FD\u6027\u304C\u4F4E\u3044\u306A\u3069\u3001\u65E2\u5B58\u306E\u85AC\u7269\u3088\u308A\u3082\u526F\u4F5C\u7528\u304C\u5C11\u306A\u3044\u3053\u3068\u304C\u591A\u3044\u3002 \u7D30\u80DE\u30D9\u30FC\u30B9\u306E\u514D\u75AB\u7642\u6CD5\u306F\u3001\u3044\u304F\u3064\u304B\u306E\u304C\u3093\u306B\u5BFE\u3057\u3066\u6709\u52B9\u3067\u3042\u308B\u3002\u30EA\u30F3\u30D1\u7403\u3001\u30DE\u30AF\u30ED\u30D5\u30A1\u30FC\u30B8\u3001\u6A39\u72B6\u7D30\u80DE\u3001\u30CA\u30C1\u30E5\u30E9\u30EB\u30AD\u30E9\u30FC\u7D30\u80DE\uFF08NK\u7D30\u80DE\uFF09\u3001\u7D30\u80DE\u50B7\u5BB3\u6027T\u30EA\u30F3\u30D1\u7403\uFF08CTL\uFF09\u306A\u3069\u306E\u514D\u75AB\u7D30\u80DE\u306F\u3001\u816B\u760D\u7D30\u80DE\u306E\u8868\u9762\u4E0A\u306B\u767A\u73FE\u3059\u308B\u7570\u5E38\u6297\u539F\u3092\u6A19\u7684\u306B\u3057\u3066\u304C\u3093\u7D30\u80DE\u3092\u6392\u9664\u3059\u308B\u3002\u9846\u7C92\u7403\u30B3\u30ED\u30CB\u30FC\u523A\u6FC0\u56E0\u5B50\uFF08G-CSF\uFF09\u3001\u30A4\u30F3\u30BF\u30FC\u30D5\u30A7\u30ED\u30F3\u3001\u30A4\u30DF\u30AD\u30E2\u30C9\u3001\u304A\u3088\u3073\u7D30\u83CC\u7531\u6765\u306E\u7D30\u80DE\u819C\u753B\u5206\u306A\u3069\u3092\u4F7F\u3063\u305F\u6CBB\u7642\u6CD5\u306F\u3001\u533B\u7642\u7528\u9014\u3067\u8A8D\u53EF\u3055\u308C\u3066\u3044\u308B\u3002 IL-2\u3001IL-7\u3001IL-12\u3001\u7A2E\u3005\u306E\u30B1\u30E2\u30AB\u30A4\u30F3\u3001\u5408\u6210\u30B7\u30C8\u30B7\u30F3\u30EA\u30F3\u9178\u30B0\u30A2\u30CE\u30B7\u30F3\uFF08CpG\uFF09\u30AA\u30EA\u30B4\u30C7\u30AA\u30AD\u30B7\u30CC\u30AF\u30EC\u30AA\u30C1\u30C9\u304A\u3088\u3073\u30B0\u30EB\u30AB\u30F3\u3092\u542B\u3080\u4ED6\u306E\u3082\u306E\u306F\u3001\u81E8\u5E8A\u8A66\u9A13\u3001\u3042\u308B\u3044\u306F\u524D\u81E8\u5E8A\u6BB5\u968E\u3067\u3042\u308B\u3002"@ja . . . . . . . . "\uBA74\uC5ED\uC694\uBC95(\u514D\u75AB\u7642\u6CD5, \uC601\uC5B4: Immunotherapy)\uC740 \uAE30\uBCF8\uC801\uC73C\uB85C \uBA74\uC5ED\uD559\uC801 \uBC29\uBC95\uC73C\uB85C \uD658\uC790 \uCE58\uB8CC\uB97C \uAE30\uD68D\uD558\uB294 \uAC83\uC744 \uB9D0\uD55C\uB2E4. \uBA74\uC5ED\uC694\uBC95\uC740 \uD06C\uAC8C \uD2B9\uC815 \uD56D\uC6D0\uC5D0 \uB300\uD55C \uBA74\uC5ED \uBC18\uC751\uC5D0\uB9CC \uAD00\uC5EC\uD558\uB294 \uD2B9\uC774\uC801 \uBA74\uC5ED\uC694\uBC95(activation immunotherapies)\uACFC \uC804\uCCB4 \uBA74\uC5ED\uACC4\uC5D0 \uAD00\uC5EC\uD558\uB294 \uBE44\uD2B9\uC774\uC801 \uBA74\uC5ED\uC694\uBC95(suppression immunotherapies)\uC774 \uC788\uB2E4. \uAC10\uC5FC\uC774 \uC6D0\uC778\uC77C \uACBD\uC6B0\uC5D0\uB294 \uBCD1\uC6D0\uCCB4\uB098 \uAC10\uC5FC\uC6D0\uC758 \uB3C5\uC18C\uC5D0 \uB300\uD55C \uBA74\uC5ED\uCCB4\uB97C \uCCB4\uB0B4\uC5D0 \uC774\uC785\uD558\uAC70\uB098, \uC778\uACF5\uC801\uC73C\uB85C \uBA74\uC5ED\uCCB4\uB97C \uC0DD\uC0B0 \uB610\uB294 \uC99D\uAC15\uC2DC\uCF1C \uCE58\uB8CC\uC5D0 \uB3C4\uC6C0\uC744 \uC900\uB2E4. \uBA74\uC5ED \uC694\uBC95\uC774 \uB2E4\uC591\uD55C \uC554\uC744 \uCE58\uB8CC\uD560 \uC218 \uC788\uB2E4\uB294 \uC810\uC5D0\uC11C \uC5F0\uAD6C\uC6D0, \uC784\uC0C1 \uBC0F \uC81C\uC57D\uD68C\uC0AC\uAC00 \uB192\uC740 \uAD00\uC2EC\uC744 \uBCF4\uC774\uACE0 \uC788\uB2E4.\uC774\uC5D0 \uB530\uB77C \uD658\uC790 \uCE58\uB8CC\uAC00 \uB354 \uBCF5\uC7A1\uD574\uC9C8 \uBFD0 \uC544\uB2C8\uB77C \uC554 \uCE58\uB8CC\uC758 \uAE30\uC900\uB3C4 \uBC14\uB00C\uACE0 \uC788\uB2E4. \uBA74\uC5ED \uC870\uC808(immunomodulatory) \uC57D\uBB3C\uC740 \uD604\uC7AC \uC2E0\uCCB4\uC5D0 \uBBF8\uCE58\uB294 \uC601\uD5A5\uC774 \uC54C\uB824\uC9C0\uC9C0 \uC54A\uC558\uB2E4. \uC138\uD3EC \uAE30\uBC18 \uBA74\uC5ED\uC694\uBC95\uC740 \uC77C\uBD80 \uC554\uC5D0 \uD6A8\uACFC\uC801\uC774\uB2E4. \uB9BC\uD504\uAD6C, \uB300\uC2DD\uC138\uD3EC, \uC218\uC9C0\uC0C1\uC138\uD3EC, \uC790\uC5F0\uC0B4\uD574\uC138\uD3EC (NK Cell), \uC138\uD3EC\uB3C5\uC131 T\uC138\uD3EC (CTL) \uAC19\uC740 \uBA74\uC5ED \uD6A8\uACFC\uAE30 \uC138\uD3EC\uAC00 \uD568\uAED8 \uC791\uC6A9\uD558\uC5EC \uC885\uC591 \uC138\uD3EC \uD45C\uBA74\uC5D0 \uBC1C\uD604\uB41C \uBE44\uC815\uC0C1 \uD56D\uC6D0\uC744 \uD45C\uC801\uC73C\uB85C \uC0BC\uC544 \uC554\uC73C\uB85C\uBD80\uD130 \uC2E0\uCCB4\uB97C \uBC29\uC5B4\uD55C\uB2E4. \uBA74\uC5ED\uC694\uBC95 \uC911 (G-CSF), \uC778\uD130\uD398\uB860, \uBC0F \uC138\uADE0\uC758 \uC138\uD3EC\uB9C9 \uBD84\uD68D\uACFC \uAC19\uC740 \uCE58\uB8CC\uBC95\uC740 \uC774\uBBF8 \uC758\uB8CC\uC6A9\uC73C\uB85C \uD5C8\uAC00\uB418\uC5C8\uB2E4. , , , \uB2E4\uC591\uD55C \uCF00\uBAA8\uCE74\uC778, \uD569\uC131 \uC2DC\uD1A0\uC2E0 \uC778\uC0B0-\uAD6C\uC544\uB178\uC2E0(CpG) \uC62C\uB9AC\uACE0\uB370\uC625\uC2DC\uB274\uD074\uB808\uC624\uD0C0\uC774\uB4DC \uBC0F \uC744 \uD3EC\uD568\uD55C \uAE30\uD0C0 \uBB3C\uC9C8\uC740 \uC784\uC0C1 \uBC0F \uC804\uC784\uC0C1 \uC5F0\uAD6C \uC9C4\uD589 \uC911\uC5D0 \uC788\uB2E4."@ko . "\u514D\u75AB\u7642\u6CD5"@ja . . "Immunoterapia edo terapia biologikoa tratamendu mediku mota bat da, immunitate-sistemaren aktibazioan datzana minbiziari -bereziki- eta beste gaixotasun batzuei (gaitz autoimmuneak, endekapen-gaitzak...) aurre egiteko. Terapia honetan erabiltzen diren substantzien artean antigorputz monoklonalak, txertoak eta interferoia, besteak beste, daude. Kimioterapia klasikoaren aldean, immunoterapiak gorputzak berak ekoizten dituen substantziak erabiltzen ditu agente terapeutiko gisa. Hortik datorkio terapia biologikoaren izena. Immunoterapia profilaktikoa edo terapeutikoa izan daiteke."@eu . . . "\u0639\u0644\u0627\u062C \u0645\u0646\u0627\u0639\u064A"@ar . . . "Immunotherapie"@nl . "Immunotherapie of immuuntherapie is een therapie, die er op is gericht het immuunsysteem zo te laten functioneren dat het lichaam zich zo goed mogelijk tegen vreemde factoren verzet. Het is een geneesmiddel, dat afhankelijk van de ziekte dat het moet bestrijden op een verschillende manier wordt toegediend. Welk geneesmiddel wordt gebruikt hangt dus van de therapie af. Soms is het wenselijk dat de afweer gestimuleerd wordt om ziekte op te lossen, soms juist dat het immuunsysteem wordt geremd. Immuunsysteem en afweersysteem zijn synoniem. Er zijn vormen van kanker waar immunotherapie goed tegen kan worden ingezet, maar er zijn ook andere situaties, bijvoorbeeld bij een allergie, waarbij immunotherapie kan helpen."@nl . . . . . . . . . . . . . . . . "\u0406\u043C\u0443\u043D\u043E\u0442\u0435\u0440\u0430\u043F\u0456\u044F"@uk . . . . . . . . . "Immunoterapia o terapia biologica \u00E8 il trattamento della malattia mediante l'attivazione o la soppressione del sistema immunitario. Immunoterapie progettate per suscitare o amplificare la risposta immunitaria sono classificati come l'attivazione di immunoterapie, mentre immunoterapie per ridurre o sopprimere sono classificati come terapie di immunodepressione. Negli ultimi anni, l'immunoterapia \u00E8 diventata di grande interesse per ricercatori, clinici e aziende farmaceutiche, in particolare nella sua promessa di trattare varie forme di cancro."@it . . . "A imunoterapia \u00E9 um ramo da terapia que cuida do tratamento e imunoprofilaxia de doen\u00E7as infecciosas, al\u00E9rgicas, parasitarias e cancer\u00EDgenas . Usando como meio recursos imunol\u00F3gicos. Experi\u00EAncias com multiplica\u00E7\u00E3o de linf\u00F3citos ativados, retirados da bi\u00F3psia e cultivados, tem tido sucesso em bom percentual de casos de c\u00E2ncer. Esta abordagem explora o fato de que as c\u00E9lulas cancer\u00EDgenas frequentemente possuem mol\u00E9culas em sua superf\u00EDcie que podem ser detectadas pelo sistema imunol\u00F3gico, conhecidas como ant\u00EDgenos tumorais. Uma grande quantidade de c\u00E2nceres humanos tem ant\u00EDgenos incluindo linfoma de Burkitt, neuroblastoma, melanoma maligno, osteossarcoma, carcinoma de c\u00E9lulas renais, cancro de mama, c\u00E2ncer de pr\u00F3stata, c\u00E2nceres pulmonares e c\u00E2ncer de c\u00F3lon. Muitas vezes s\u00E3o prote\u00EDnas ou outra"@pt . "Imunoterapia"@pt . . . . "\u0627\u0644\u0639\u0644\u0627\u062C \u0627\u0644\u0645\u0646\u0627\u0639\u064A \u0647\u0648 \u0639\u0644\u0627\u062C \u0627\u0644\u0645\u0631\u0636 \u0639\u0646 \u0637\u0631\u064A\u0642 \u062A\u0646\u0634\u064A\u0637 \u0623\u0648 \u062A\u062B\u0628\u064A\u0637 \u0627\u0644\u062C\u0647\u0627\u0632 \u0627\u0644\u0645\u0646\u0627\u0639\u064A\u060C \u0641\u0627\u0644\u0639\u0644\u0627\u062C \u0627\u0644\u0645\u0646\u0627\u0639\u064A \u0627\u0644\u0642\u0627\u0626\u0645 \u0639\u0644\u0649 \u0625\u062B\u0627\u0631\u0629 \u0623\u0648 \u062A\u0636\u062E\u064A\u0645 \u0631\u062F \u0641\u0639\u0644 \u0627\u0644\u062C\u0647\u0627\u0632 \u0627\u0644\u0645\u0646\u0627\u0639\u064A \u064A\u062A\u0645 \u062A\u0635\u0646\u064A\u0641\u0647 \u0643\u0639\u0644\u0627\u062C \u0645\u0646\u0627\u0639\u064A \u062A\u0646\u0634\u064A\u0637\u064A\u060C \u0628\u064A\u0646\u0645\u0627 \u0627\u0644\u0639\u0644\u0627\u062C \u0627\u0644\u0645\u0646\u0627\u0639\u064A \u0627\u0644\u0642\u0627\u0626\u0645 \u0639\u0644\u0649 \u062A\u0642\u0644\u064A\u0644\u0647 \u0623\u0648 \u0625\u062E\u0645\u0627\u062F\u0647 \u064A\u062A\u0645 \u062A\u0635\u0646\u064A\u0641\u0647 \u0643\u0639\u0644\u0627\u062C \u0645\u0646\u0627\u0639\u064A \u062A\u062B\u0628\u064A\u0637\u064A. \u0648\u0642\u062F \u0632\u0627\u062F \u0627\u0644\u0627\u0647\u062A\u0645\u0627\u0645 \u0643\u062B\u064A\u0631\u064B\u0627 \u0639\u0646\u062F \u0627\u0644\u0628\u0627\u062D\u062B\u064A\u0646 \u0641\u064A \u0627\u0644\u0633\u0646\u0648\u0627\u062A \u0627\u0644\u0623\u062E\u064A\u0631\u0629 \u0628\u0627\u0644\u0639\u0644\u0627\u062C \u0627\u0644\u0645\u0646\u0627\u0639\u064A \u0648\u062E\u0627\u0635\u0629\u064B \u0628\u0625\u0645\u0643\u0627\u0646\u064A\u0629 \u0639\u0644\u0627\u062C\u0647 \u0644\u0623\u0646\u0648\u0627\u0639 \u0645\u062E\u062A\u0644\u0641\u0629 \u0645\u0646 \u0627\u0644\u0633\u0631\u0637\u0627\u0646. \u0639\u0627\u062F\u0629\u064B \u0645\u0627 \u064A\u0643\u0648\u0646 \u0644\u0623\u0646\u0638\u0645\u0629 \u062A\u0639\u062F\u064A\u0644 \u0627\u0644\u0645\u0646\u0627\u0639\u0629 \u0622\u062B\u0627\u0631 \u062C\u0627\u0646\u0628\u064A\u0629 \u0623\u0642\u0644 \u0645\u0646 \u0627\u0644\u0623\u062F\u0648\u064A\u0629 \u0627\u0644\u0645\u0648\u062C\u0648\u062F\u0629 \u062D\u0627\u0644\u064A\u064B\u0627\u060C \u0628\u0645\u0627 \u0641\u064A \u0630\u0644\u0643 \u0627\u0644\u0627\u062D\u062A\u0645\u0627\u0644\u064A\u0629 \u0627\u0644\u0623\u0642\u0644 \u0644\u062E\u0644\u0642 \u0645\u0642\u0627\u0648\u0645\u0629 \u0639\u0646\u062F \u0645\u0639\u0627\u0644\u062C\u0629 \u0627\u0644\u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0645\u064A\u0643\u0631\u0648\u0628\u064A\u0629."@ar . . . . . . . . . . . . "\u0627\u0644\u0639\u0644\u0627\u062C \u0627\u0644\u0645\u0646\u0627\u0639\u064A \u0647\u0648 \u0639\u0644\u0627\u062C \u0627\u0644\u0645\u0631\u0636 \u0639\u0646 \u0637\u0631\u064A\u0642 \u062A\u0646\u0634\u064A\u0637 \u0623\u0648 \u062A\u062B\u0628\u064A\u0637 \u0627\u0644\u062C\u0647\u0627\u0632 \u0627\u0644\u0645\u0646\u0627\u0639\u064A\u060C \u0641\u0627\u0644\u0639\u0644\u0627\u062C \u0627\u0644\u0645\u0646\u0627\u0639\u064A \u0627\u0644\u0642\u0627\u0626\u0645 \u0639\u0644\u0649 \u0625\u062B\u0627\u0631\u0629 \u0623\u0648 \u062A\u0636\u062E\u064A\u0645 \u0631\u062F \u0641\u0639\u0644 \u0627\u0644\u062C\u0647\u0627\u0632 \u0627\u0644\u0645\u0646\u0627\u0639\u064A \u064A\u062A\u0645 \u062A\u0635\u0646\u064A\u0641\u0647 \u0643\u0639\u0644\u0627\u062C \u0645\u0646\u0627\u0639\u064A \u062A\u0646\u0634\u064A\u0637\u064A\u060C \u0628\u064A\u0646\u0645\u0627 \u0627\u0644\u0639\u0644\u0627\u062C \u0627\u0644\u0645\u0646\u0627\u0639\u064A \u0627\u0644\u0642\u0627\u0626\u0645 \u0639\u0644\u0649 \u062A\u0642\u0644\u064A\u0644\u0647 \u0623\u0648 \u0625\u062E\u0645\u0627\u062F\u0647 \u064A\u062A\u0645 \u062A\u0635\u0646\u064A\u0641\u0647 \u0643\u0639\u0644\u0627\u062C \u0645\u0646\u0627\u0639\u064A \u062A\u062B\u0628\u064A\u0637\u064A. \u0648\u0642\u062F \u0632\u0627\u062F \u0627\u0644\u0627\u0647\u062A\u0645\u0627\u0645 \u0643\u062B\u064A\u0631\u064B\u0627 \u0639\u0646\u062F \u0627\u0644\u0628\u0627\u062D\u062B\u064A\u0646 \u0641\u064A \u0627\u0644\u0633\u0646\u0648\u0627\u062A \u0627\u0644\u0623\u062E\u064A\u0631\u0629 \u0628\u0627\u0644\u0639\u0644\u0627\u062C \u0627\u0644\u0645\u0646\u0627\u0639\u064A \u0648\u062E\u0627\u0635\u0629\u064B \u0628\u0625\u0645\u0643\u0627\u0646\u064A\u0629 \u0639\u0644\u0627\u062C\u0647 \u0644\u0623\u0646\u0648\u0627\u0639 \u0645\u062E\u062A\u0644\u0641\u0629 \u0645\u0646 \u0627\u0644\u0633\u0631\u0637\u0627\u0646. \u0639\u0627\u062F\u0629\u064B \u0645\u0627 \u064A\u0643\u0648\u0646 \u0644\u0623\u0646\u0638\u0645\u0629 \u062A\u0639\u062F\u064A\u0644 \u0627\u0644\u0645\u0646\u0627\u0639\u0629 \u0622\u062B\u0627\u0631 \u062C\u0627\u0646\u0628\u064A\u0629 \u0623\u0642\u0644 \u0645\u0646 \u0627\u0644\u0623\u062F\u0648\u064A\u0629 \u0627\u0644\u0645\u0648\u062C\u0648\u062F\u0629 \u062D\u0627\u0644\u064A\u064B\u0627\u060C \u0628\u0645\u0627 \u0641\u064A \u0630\u0644\u0643 \u0627\u0644\u0627\u062D\u062A\u0645\u0627\u0644\u064A\u0629 \u0627\u0644\u0623\u0642\u0644 \u0644\u062E\u0644\u0642 \u0645\u0642\u0627\u0648\u0645\u0629 \u0639\u0646\u062F \u0645\u0639\u0627\u0644\u062C\u0629 \u0627\u0644\u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0645\u064A\u0643\u0631\u0648\u0628\u064A\u0629. \u064A\u0639\u062F \u0627\u0644\u0639\u0644\u0627\u062C \u0627\u0644\u0645\u0646\u0627\u0639\u064A \u0627\u0644\u062E\u0644\u0648\u064A \u0645\u0624\u062B\u0631\u064B\u0627 \u0645\u0639 \u0628\u0639\u0636 \u0623\u0646\u0648\u0627\u0639 \u0627\u0644\u0633\u0631\u0637\u0627\u0646\u060C \u0641\u0627\u0644\u062E\u0644\u0627\u064A\u0627 \u0627\u0644\u0645\u0624\u062B\u0631\u0629 \u0641\u064A \u0627\u0644\u0645\u0646\u0627\u0639\u0629 \u0645\u062B\u0644 \u0627\u0644\u0644\u064A\u0645\u0641\u0627\u0648\u064A\u0627\u062A \u0648\u0627\u0644\u0628\u0644\u0627\u0639\u0645 \u0648\u0627\u0644\u062E\u0644\u0627\u064A\u0627 \u0627\u0644\u0645\u062A\u063A\u0635\u0646\u0629 \u0648\u0627\u0644\u062E\u0644\u0627\u064A\u0627 \u0627\u0644\u0641\u0627\u062A\u0643\u0629 \u0627\u0644\u0637\u0628\u064A\u0639\u064A\u0629 \u0648\u062E\u0644\u0627\u064A\u0627 \u062A\u064A \u0627\u0644\u0642\u0627\u062A\u0644\u0629 \u0648\u0645\u0627 \u0625\u0644\u0649 \u0630\u0644\u0643 \u062A\u0639\u0645\u0644 \u0645\u0639\u064B\u0627 \u0644\u0644\u062F\u0641\u0627\u0639 \u0639\u0646 \u0627\u0644\u062C\u0633\u0645 \u0636\u062F \u0627\u0644\u0633\u0631\u0637\u0627\u0646 \u0639\u0646 \u0637\u0631\u064A\u0642 \u0627\u0633\u062A\u0647\u062F\u0627\u0641 \u0627\u0644\u0645\u0648\u0644\u062F\u0627\u062A \u0627\u0644\u0645\u0636\u0627\u062F\u0629 \u0627\u0644\u0645\u062A\u0643\u0648\u0646\u0629 \u0639\u0644\u0649 \u0633\u0637\u062D \u062E\u0644\u0627\u064A\u0627 \u0627\u0644\u0648\u0631\u0645. \u0644\u0642\u062F \u062A\u0645 \u062A\u0631\u062E\u064A\u0635 \u0627\u0644\u0639\u0644\u0627\u062C\u0627\u062A \u0645\u062B\u0644 \u0639\u0627\u0645\u0644 \u062A\u062D\u0641\u064A\u0632 \u0645\u0633\u062A\u0639\u0645\u0631\u0627\u062A \u0627\u0644\u062E\u0644\u0627\u064A\u0627 \u0627\u0644\u0645\u062D\u0628\u0628\u0629 \u0648\u0625\u0646\u062A\u0631\u0641\u064A\u0631\u0648\u0646 \u0648\u0625\u0645\u064A\u0643\u0648\u064A\u0645\u0648\u062F \u0648\u0623\u062C\u0632\u0627\u0621 \u0627\u0644\u063A\u0634\u0627\u0621 \u0627\u0644\u0628\u0644\u0627\u0632\u0645\u064A \u0644\u0644\u062E\u0644\u064A\u0629 \u0644\u0644\u0627\u0633\u062A\u062E\u062F\u0627\u0645 \u0627\u0644\u0637\u0628\u064A\u060C \u0648\u0628\u0639\u0636 \u0627\u0644\u0639\u0644\u0627\u062C\u0627\u062A \u0627\u0644\u0623\u062E\u0631\u0649 \u0645\u062B\u0644 \u0625\u0646\u062A\u0631\u0644\u0648\u0643\u064A\u06462 \u0648 \u0625\u0646\u062A\u0631\u0644\u0648\u0643\u064A\u06467 \u0648 \u0625\u0646\u062A\u0631\u0644\u0648\u0643\u064A\u064612 \u0648\u0627\u0644\u0643\u064A\u0645\u0648\u0643\u064A\u0646\u0627\u062A \u0627\u0644\u0645\u062E\u062A\u0644\u0641\u0629 \u0648\u0633\u064A \u0628\u064A \u062C\u064A synthetic cytosine phosphate-guanosine (CpG) \u0648\u062C\u0644\u0648\u0643\u0627\u0646 \u062A\u0633\u062A\u062E\u062F\u0645 \u0641\u064A \u0627\u0644\u062A\u062C\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064A\u0631\u064A\u0629 \u0648 \u063A\u064A\u0631 \u0627\u0644\u0633\u0631\u064A\u0631\u064A\u0629."@ar . . . "Immunoterapia"@eu . . "\u0418\u043C\u043C\u0443\u043D\u043E\u0442\u0435\u0440\u0430\u043F\u0438\u044F (\u043B\u0430\u0442. immunis \u2014 \u0441\u0432\u043E\u0431\u043E\u0434\u043D\u044B\u0439, \u0438\u0437\u0431\u0430\u0432\u043B\u0435\u043D\u043D\u044B\u0439 \u043E\u0442 \u0447\u0435\u0433\u043E-\u043B\u0438\u0431\u043E, \u0433\u0440\u0435\u0447., therapeia \u2014 \u043B\u0435\u0447\u0435\u043D\u0438\u0435) \u2014 \u0440\u0430\u0437\u0434\u0435\u043B \u043F\u0440\u0430\u043A\u0442\u0438\u0447\u0435\u0441\u043A\u043E\u0439 \u0438\u043C\u043C\u0443\u043D\u043E\u043B\u043E\u0433\u0438\u0438, \u0437\u0430\u0434\u0430\u0447\u0430 \u043A\u043E\u0442\u043E\u0440\u043E\u0433\u043E \u2014 \u043B\u0435\u0447\u0435\u043D\u0438\u0435 \u0438\u043C\u043C\u0443\u043D\u043E\u043B\u043E\u0433\u0438\u0447\u0435\u0441\u043A\u0438\u043C\u0438 \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442\u0430\u043C\u0438, \u043A\u043E\u0442\u043E\u0440\u044B\u0435 \u0432\u043E\u0437\u0434\u0435\u0439\u0441\u0442\u0432\u0443\u044E\u0442 \u043F\u0440\u0438\u0446\u0435\u043B\u044C\u043D\u043E \u043D\u0430 \u0438\u043C\u043C\u0443\u043D\u043D\u0443\u044E \u0441\u0438\u0441\u0442\u0435\u043C\u0443: \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442\u0430\u043C\u0438 \u0430\u043D\u0442\u0438\u0442\u0435\u043B \u0438\u043B\u0438 \u0441\u044B\u0432\u043E\u0440\u043E\u0442\u043E\u043A, \u043C\u043E\u043D\u043E\u043A\u043B\u043E\u043D\u0430\u043B\u044C\u043D\u044B\u043C\u0438 \u0430\u043D\u0442\u0438\u0442\u0435\u043B\u0430\u043C\u0438, \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442\u0430\u043C\u0438 \u043C\u0438\u043A\u0440\u043E\u0431\u043D\u043E\u0433\u043E \u043F\u0440\u043E\u0438\u0441\u0445\u043E\u0436\u0434\u0435\u043D\u0438\u044F, \u0446\u0438\u0442\u043E\u043A\u0438\u043D\u043E\u0432\u0430\u044F \u0438 \u0430\u043D\u0442\u0438\u0446\u0438\u0442\u043E\u043A\u0438\u043D\u043E\u0432\u0430\u044F \u0442\u0435\u0440\u0430\u043F\u0438\u044F, \u043A\u043B\u0435\u0442\u043E\u0447\u043D\u0430\u044F \u0442\u0435\u0440\u0430\u043F\u0438\u044F. \u0418\u043C\u043C\u0443\u043D\u043E\u0442\u0435\u0440\u0430\u043F\u0438\u044E \u0432 \u043A\u0430\u0447\u0435\u0441\u0442\u0432\u0435 \u0432\u0441\u043F\u043E\u043C\u043E\u0433\u0430\u0442\u0435\u043B\u044C\u043D\u043E\u0433\u043E \u043C\u0435\u0442\u043E\u0434\u0430 \u043F\u0440\u0438\u043C\u0435\u043D\u044F\u044E\u0442 \u043F\u0440\u0438 \u0438\u043D\u0444\u0435\u043A\u0446\u0438\u043E\u043D\u043D\u044B\u0445, \u043E\u043D\u043A\u043E\u043B\u043E\u0433\u0438\u0447\u0435\u0441\u043A\u0438\u0445 \u0437\u0430\u0431\u043E\u043B\u0435\u0432\u0430\u043D\u0438\u044F\u0445, \u0432 \u044D\u0442\u043E\u043C \u0441\u043B\u0443\u0447\u0430\u0435 \u0447\u0430\u0449\u0435 \u0441\u043E\u0447\u0435\u0442\u0430\u044E\u0442 \u0441 \u043B\u0435\u0447\u0435\u043D\u0438\u0435\u043C \u0430\u043D\u0442\u0438\u0431\u0438\u043E\u0442\u0438\u043A\u0430\u043C\u0438 \u0438 \u0445\u0438\u043C\u0438\u043E\u0442\u0435\u0440\u0430\u043F\u0438\u0435\u0439. \u0418\u043C\u043C\u0443\u043D\u043E\u0442\u0435\u0440\u0430\u043F\u0438\u044F \u043F\u043E\u043A\u0430\u0437\u0430\u043D\u0430 \u043F\u0440\u0438 \u043F\u0435\u0440\u0432\u0438\u0447\u043D\u043E\u043C \u043D\u0430\u0440\u0443\u0448\u0435\u043D\u0438\u0438 \u0440\u0430\u0431\u043E\u0442\u044B \u0438\u043C\u043C\u0443\u043D\u043D\u043E\u0439 \u0441\u0438\u0441\u0442\u0435\u043C\u044B \u2014 \u0438\u043C\u043C\u0443\u043D\u043E\u0434\u0435\u0444\u0438\u0446\u0438\u0442\u0430\u0445, \u0430\u0443\u0442\u043E\u0438\u043C\u043C\u0443\u043D\u043D\u044B\u0445 \u0437\u0430\u0431\u043E\u043B\u0435\u0432\u0430\u043D\u0438\u044F\u0445."@ru . . . . . . . . . . . . . . . . . . "Immunterapi"@sv . "Immunoterapia o terapia biologica \u00E8 il trattamento della malattia mediante l'attivazione o la soppressione del sistema immunitario. Immunoterapie progettate per suscitare o amplificare la risposta immunitaria sono classificati come l'attivazione di immunoterapie, mentre immunoterapie per ridurre o sopprimere sono classificati come terapie di immunodepressione. Negli ultimi anni, l'immunoterapia \u00E8 diventata di grande interesse per ricercatori, clinici e aziende farmaceutiche, in particolare nella sua promessa di trattare varie forme di cancro. I regimi immunomodulatori hanno spesso un minor numero di effetti collaterali rispetto ai farmaci esistenti, incluso un minor potenziale di resistenza nel trattamento delle malattie microbiche. Le immunoterapie a base cellulare sono efficaci per alcuni tumori. Le cellule effettrici immunitarie come linfociti, macrofagi, cellule dendritiche, cellule killer naturali (cellule NK), linfociti T citotossici (CTL), ecc., lavorano insieme per difendere il corpo dal cancro colpendo gli antigeni anomali espressi sulla superficie delle cellule tumorali. Terapie come il fattore stimolante le colonie di granulociti (G-CSF), interferoni, imiquimod e frazioni di membrana cellulare da batteri sono concesse in licenza per uso medico. Altri, inclusi IL-2, IL-7, IL-12, varie chemochine, citosina fosfato-guanosina sintetica (CpG), oligodeossinucleotidi e glucani sono coinvolti in studi clinici e preclinici."@it . . . "\u0391\u03BD\u03BF\u03C3\u03BF\u03B8\u03B5\u03C1\u03B1\u03C0\u03B5\u03AF\u03B1"@el . "Immunotherapy"@en . . . . . "Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies. Immunotherapy is under preliminary research for its potential to treat various forms of cancer."@en . "Immunotherapie of immuuntherapie is een therapie, die er op is gericht het immuunsysteem zo te laten functioneren dat het lichaam zich zo goed mogelijk tegen vreemde factoren verzet. Het is een geneesmiddel, dat afhankelijk van de ziekte dat het moet bestrijden op een verschillende manier wordt toegediend. Welk geneesmiddel wordt gebruikt hangt dus van de therapie af. Soms is het wenselijk dat de afweer gestimuleerd wordt om ziekte op te lossen, soms juist dat het immuunsysteem wordt geremd. Immuunsysteem en afweersysteem zijn synoniem. Er zijn vormen van kanker waar immunotherapie goed tegen kan worden ingezet, maar er zijn ook andere situaties, bijvoorbeeld bij een allergie, waarbij immunotherapie kan helpen. Het is in het geval van kankerimmunotherapie de bedoeling dat het immuunsysteem wordt geactiveerd om tumoren op te ruimen. Kankerimmunotherapie is vooral goed voor het afstoten van de uitzaaiingen, van de metastasen van kanker. James Allison en Tasuku Honjo kregen in 2018 de Nobelprijs voor Fysiologie of Geneeskunde voor hun onderzoek naar immunotherapie. Bij een orgaantransplantatie wil men afstotingsreacties juist remmen, zodat het vreemde orgaan behouden blijft en ook bij auto-immuunziekten is het de bedoeling afweerreacties te remmen. Toediening door middel van inenting valt strikt genomen ook onder de definitie van immunotherapie, maar wordt daar meestal niet toe gerekend."@nl . . . . "1118537042"^^ . . . . . . . . . . "Immunoterapi \u00E4r behandling av sjukdom med immunologiska metoder."@sv . "Immunoth\u00E9rapie"@fr . . "\u0406\u043C\u0443\u043D\u043E\u0442\u0435\u0440\u0430\u043F\u0456\u0301\u044F \u2014 \u0440\u043E\u0437\u0434\u0456\u043B \u043F\u0440\u0430\u043A\u0442\u0438\u0447\u043D\u043E\u0457 \u0456\u043C\u0443\u043D\u043E\u043B\u043E\u0433\u0456\u0457, \u0437\u0430\u0432\u0434\u0430\u043D\u043D\u044F\u043C \u044F\u043A\u043E\u0433\u043E \u0454 \u043B\u0456\u043A\u0443\u0432\u0430\u043D\u043D\u044F \u0456\u043C\u0443\u043D\u043E\u0431\u0456\u043E\u043B\u043E\u0433\u0456\u0447\u043D\u0438\u043C\u0438 \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442\u0430\u043C\u0438 \u2014 \u0432\u0430\u043A\u0446\u0438\u043D\u0430\u043C\u0438, \u0441\u0438\u0440\u043E\u0432\u0430\u0442\u043A\u0430\u043C\u0438, \u0456\u043D\u0442\u0435\u0440\u0444\u0435\u0440\u043E\u043D\u0430\u043C\u0438, \u0431\u0430\u043A\u0442\u0435\u0440\u0456\u043E\u0444\u0430\u0433\u0430\u043C\u0438, \u0430\u043B\u0435\u0440\u0433\u0435\u043D\u0430\u043C\u0438 \u0442\u0430 \u0456\u043D\u0448\u0438\u043C. \u0412\u0456\u0434\u043D\u043E\u0441\u043D\u043E \u0435\u0442\u0456\u043E\u043B\u043E\u0433\u0456\u0447\u043D\u043E\u0433\u043E \u0447\u0438\u043D\u043D\u0438\u043A\u0430 \u0432\u0438\u0434\u0456\u043B\u044F\u044E\u0442\u044C \u0456\u043C\u0443\u043D\u043E\u0442\u0435\u0440\u0430\u043F\u0456\u044E: \n* \u0441\u043F\u0435\u0446\u0438\u0444\u0456\u0447\u043D\u0443 \n* \u043D\u0435\u0441\u043F\u0435\u0446\u0438\u0444\u0456\u0447\u043D\u0443 \u0412\u0456\u0434\u043D\u043E\u0441\u043D\u043E \u043E\u0440\u0433\u0430\u043D\u0456\u0437\u043C\u0443 \u043F\u0430\u0446\u0456\u0454\u043D\u0442\u0430: \n* \u0430\u043A\u0442\u0438\u0432\u043D\u0443 \n* \u043F\u0430\u0441\u0438\u0432\u043D\u0443 \u041F\u0435\u0440\u0435\u0432\u0430\u0433\u043E\u044E \u0456\u043C\u0443\u043D\u043E\u0442\u0435\u0440\u0430\u043F\u0456\u0457 \u0454 \u043C\u043E\u0436\u043B\u0438\u0432\u0456\u0441\u0442\u044C \u043F\u0440\u043E\u0432\u0435\u0434\u0435\u043D\u043D\u044F \u043B\u0456\u043A\u0443\u0432\u0430\u043D\u043D\u044F \u0437 \u0443\u0440\u0430\u0445\u0443\u0432\u0430\u043D\u043D\u044F\u043C \u043A\u043E\u043D\u043A\u0440\u0435\u0442\u043D\u043E\u0433\u043E (\u0441\u043F\u0435\u0446\u0438\u0444\u0456\u0447\u043D\u043E\u0433\u043E) \u0435\u0442\u0456\u043E\u043B\u043E\u0433\u0456\u0447\u043D\u043E\u0433\u043E \u0447\u0438\u043D\u043D\u0438\u043A\u0430 \u0437\u0430\u0445\u0432\u043E\u0440\u044E\u0432\u0430\u043D\u043D\u044F (\u0456\u043D\u0444\u0435\u043A\u0446\u0456\u0439\u043D\u043E\u0433\u043E, \u0430\u043B\u0435\u0440\u0433\u0456\u0447\u043D\u043E\u0433\u043E). \u0422\u043E\u043C\u0443 \u043D\u0430\u0439\u0447\u0430\u0441\u0442\u0456\u0448\u0435 \u0432\u0438\u043A\u043E\u0440\u0438\u0441\u0442\u043E\u0432\u0443\u044E\u0442\u044C \u0441\u0430\u043C\u0435 \u0441\u043F\u0435\u0446\u0438\u0444\u0456\u0447\u043D\u0443 \u0456\u043C\u0443\u043D\u043E\u0442\u0435\u0440\u0430\u043F\u0456\u044E."@uk . . . . . . . . . . . "Immunoterapia \u2013 zbi\u00F3r metod polegaj\u0105cych na modyfikacji czynno\u015Bci uk\u0142adu odporno\u015Bciowego. Obejmuje: \n* immunosupresj\u0119 \n* \n* Stosuje si\u0119 je mi\u0119dzy innymi w leczeniu nowotwor\u00F3w, chor\u00F3b autoimmunologicznych i transplantologii. Immunoterapi\u0119 dzieli si\u0119 na: \n* lokaln\u0105 (dotyczy jednej cz\u0119\u015Bci cia\u0142a) \n* ca\u0142o\u015Bciow\u0105 (dotyczy ca\u0142ego cia\u0142a; np. zastosowanie interferonu-alfa oraz genu interleukin-2 IL-2) lub: \n* niespecyficzn\u0105 tzw. immunoterapia nieswoista (stymuluje si\u0119 system odporno\u015Bciowy chorego do og\u00F3lnie lepszego dzia\u0142ania) \n* celowan\u0105 tzw. immunoterapia swoista (nakierowana na konkretny rodzaj kom\u00F3rek, kt\u00F3re maj\u0105 by\u0107 zwalczane \u2013 z wykorzystaniem przeciwcia\u0142 monoklonalnych lub \"szczepionek\""@pl . "Imunoterapi"@in . "Imunoterapi adalah pengobatan penyakit dengan mengaktifkan atau menekan sistem imun. Imunoterapi yang dirancang untuk memperoleh atau memperkuat respons imun diklasifikasikan sebagai imunoterapi aktivasi, sedangkan imunoterapi yang mengurangi atau menekan diklasifikasikan sebagai imunoterapi penekan. Dalam beberapa tahun terakhir, imunoterapi telah menjadi sangat menarik bagi para peneliti, dokter dan perusahaan farmasi, terutama dalam prospeknya untuk mengobati berbagai bentuk kanker."@in . . . "\u514D\u75AB\u6CBB\u7597"@zh . "\uBA74\uC5ED\uC694\uBC95(\u514D\u75AB\u7642\u6CD5, \uC601\uC5B4: Immunotherapy)\uC740 \uAE30\uBCF8\uC801\uC73C\uB85C \uBA74\uC5ED\uD559\uC801 \uBC29\uBC95\uC73C\uB85C \uD658\uC790 \uCE58\uB8CC\uB97C \uAE30\uD68D\uD558\uB294 \uAC83\uC744 \uB9D0\uD55C\uB2E4. \uBA74\uC5ED\uC694\uBC95\uC740 \uD06C\uAC8C \uD2B9\uC815 \uD56D\uC6D0\uC5D0 \uB300\uD55C \uBA74\uC5ED \uBC18\uC751\uC5D0\uB9CC \uAD00\uC5EC\uD558\uB294 \uD2B9\uC774\uC801 \uBA74\uC5ED\uC694\uBC95(activation immunotherapies)\uACFC \uC804\uCCB4 \uBA74\uC5ED\uACC4\uC5D0 \uAD00\uC5EC\uD558\uB294 \uBE44\uD2B9\uC774\uC801 \uBA74\uC5ED\uC694\uBC95(suppression immunotherapies)\uC774 \uC788\uB2E4. \uAC10\uC5FC\uC774 \uC6D0\uC778\uC77C \uACBD\uC6B0\uC5D0\uB294 \uBCD1\uC6D0\uCCB4\uB098 \uAC10\uC5FC\uC6D0\uC758 \uB3C5\uC18C\uC5D0 \uB300\uD55C \uBA74\uC5ED\uCCB4\uB97C \uCCB4\uB0B4\uC5D0 \uC774\uC785\uD558\uAC70\uB098, \uC778\uACF5\uC801\uC73C\uB85C \uBA74\uC5ED\uCCB4\uB97C \uC0DD\uC0B0 \uB610\uB294 \uC99D\uAC15\uC2DC\uCF1C \uCE58\uB8CC\uC5D0 \uB3C4\uC6C0\uC744 \uC900\uB2E4. \uBA74\uC5ED \uC694\uBC95\uC774 \uB2E4\uC591\uD55C \uC554\uC744 \uCE58\uB8CC\uD560 \uC218 \uC788\uB2E4\uB294 \uC810\uC5D0\uC11C \uC5F0\uAD6C\uC6D0, \uC784\uC0C1 \uBC0F \uC81C\uC57D\uD68C\uC0AC\uAC00 \uB192\uC740 \uAD00\uC2EC\uC744 \uBCF4\uC774\uACE0 \uC788\uB2E4.\uC774\uC5D0 \uB530\uB77C \uD658\uC790 \uCE58\uB8CC\uAC00 \uB354 \uBCF5\uC7A1\uD574\uC9C8 \uBFD0 \uC544\uB2C8\uB77C \uC554 \uCE58\uB8CC\uC758 \uAE30\uC900\uB3C4 \uBC14\uB00C\uACE0 \uC788\uB2E4. \uBA74\uC5ED \uC870\uC808(immunomodulatory) \uC57D\uBB3C\uC740 \uD604\uC7AC \uC2E0\uCCB4\uC5D0 \uBBF8\uCE58\uB294 \uC601\uD5A5\uC774 \uC54C\uB824\uC9C0\uC9C0 \uC54A\uC558\uB2E4. \uC138\uD3EC \uAE30\uBC18 \uBA74\uC5ED\uC694\uBC95\uC740 \uC77C\uBD80 \uC554\uC5D0 \uD6A8\uACFC\uC801\uC774\uB2E4. \uB9BC\uD504\uAD6C, \uB300\uC2DD\uC138\uD3EC, \uC218\uC9C0\uC0C1\uC138\uD3EC, \uC790\uC5F0\uC0B4\uD574\uC138\uD3EC (NK Cell), \uC138\uD3EC\uB3C5\uC131 T\uC138\uD3EC (CTL) \uAC19\uC740 \uBA74\uC5ED \uD6A8\uACFC\uAE30 \uC138\uD3EC\uAC00 \uD568\uAED8 \uC791\uC6A9\uD558\uC5EC \uC885\uC591 \uC138\uD3EC \uD45C\uBA74\uC5D0 \uBC1C\uD604\uB41C \uBE44\uC815\uC0C1 \uD56D\uC6D0\uC744 \uD45C\uC801\uC73C\uB85C \uC0BC\uC544 \uC554\uC73C\uB85C\uBD80\uD130 \uC2E0\uCCB4\uB97C \uBC29\uC5B4\uD55C\uB2E4."@ko . . . . . "L'immunoth\u00E9rapie consiste \u00E0 administrer des substances stimulant les d\u00E9fenses immunitaires du malade contre des infections, certains cancers h\u00E9matologiques (autrement dit, du sang), des maladies d\u00E9g\u00E9n\u00E9ratives ou auto-immunes. Ceci inclut les th\u00E9rapies utilisant des prot\u00E9ines (anticorps) produites par les cellules du syst\u00E8me immunitaire, en particulier les immunoglobulines, sans que l'objectif de cette th\u00E9rapie ne soit n\u00E9cessairement la stimulation de l'immunit\u00E9. On distingue l'immunoth\u00E9rapie locale (rare) et l'immunoth\u00E9rapie g\u00E9n\u00E9rale (beaucoup plus fr\u00E9quente)."@fr . "Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies. Immunotherapy is under preliminary research for its potential to treat various forms of cancer. Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells, and cytotoxic T lymphocytes work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells. Vaccine-induced immunity to COVID-19 relies mostly on an immunomodulatory T cell response. Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies."@en . . "\u514D\u75AB\u6CBB\u7597\uFF08\u82F1\u8A9E\uFF1AImmunotherapy\uFF09\uFF0C\u662F\u6307\u901A\u8FC7\u8BF1\u5BFC\u3001\u589E\u5F3A\u6216\u6291\u5236\u514D\u75AB\u53CD\u5E94\u7684\u75BE\u75C5\u6CBB\u7597\u65B9\u6CD5\u3002\u5176\u4E2D\u65E8\u5728\u5F15\u8D77\u6216\u589E\u5F3A\u514D\u75AB\u53CD\u5E94\u7684\u514D\u75AB\u7597\u6CD5\uFF0C\u79F0\u4E3A\u6FC0\u6D3B\u514D\u75AB\u7597\u6CD5\uFF08activation immunotherapies\uFF09\uFF0C\u800C\u51CF\u5C11\u6216\u6291\u5236\u514D\u75AB\u53CD\u5E94\u5219\u662F\u6291\u5236\u514D\u75AB\u7597\u6CD5\uFF08suppression immunotherapies\uFF09\u3002 \u514D\u75AB\u7597\u6CD5\u5F80\u5F80\u6BD4\u73B0\u6709\u836F\u7269\u7684\u526F\u4F5C\u7528\u5C11\uFF0C\u5305\u62EC\u51CF\u5C11\u5BF9\u5FAE\u751F\u7269\u75BE\u75C5\u7684\u6297\u836F\u6027\u53CD\u5E94\u3002 \u57FA\u4E8E\u7EC6\u80DE\u7684\u514D\u75AB\u7597\u6CD5\u5BF9\u4E00\u4E9B\u764C\u75C7\u6709\u6548\u3002\u514D\u75AB\u6548\u5E94\u7EC6\u80DE\u5982\u6DCB\u5DF4\u7EC6\u80DE\u3001\u5DE8\u566C\u7EC6\u80DE\u3001\u6811\u7A81\u72B6\u7EC6\u80DE\u3001\u81EA\u7136\u6740\u4F24\u7EC6\u80DE\uFF08NK\u7EC6\u80DE\uFF09\uFF0C\u7EC6\u80DE\u6BD2\u6027T\u6DCB\u5DF4\u7EC6\u80DE\uFF08CTL\uFF09\u7B49\uFF0C\u901A\u8FC7\u9488\u5BF9\u80BF\u7624\u7EC6\u80DE\u8868\u9762\u7684\u5F02\u5E38\u6297\u539F\uFF0C\u6765\u5171\u540C\u5E2E\u52A9\u8EAB\u4F53\u62B5\u5FA1\u764C\u75C7\u3002 \uFF08G-CSF\uFF09\u3001\u5E72\u6270\u7D20\u3001\u4E0E\u7EC6\u83CC\u7EC6\u80DE\u819C\u7EC4\u5206\u7B49\u7597\u6CD5\uFF0C\u5DF2\u7ECF\u8BB8\u53EF\u8FDB\u5165\u4E34\u5E8A\u6CBB\u7597\u3002\u5176\u4ED6\u7814\u7A76\u6709\u767D\u7EC6\u80DE\u4ECB\u7D20-2\u3001\u3001\u3001\u5404\u79CD\u8D8B\u5316\u56E0\u5B50\u3001\u4EBA\u5DE5\u5408\u6210\u7684CpG\u5BE1\u8131\u6C27\u6838\u82F7\u9178\u548C\u8461\u805A\u7CD6\u7B49\uFF0C\u8FD9\u4E9B\u5747\u5DF2\u8FDB\u5165\u4E34\u5E8A\u548C\u4E34\u5E8A\u524D\u7814\u7A76\u3002"@zh . . . "Immuntherapien sind Behandlungsformen, bei denen das Immunsystem beeinflusst wird. Hierbei kommen in Abh\u00E4ngigkeit von der Erkrankung modulierende (stimulierende und supprimierende) oder substituierende (ersetzende) Verfahren zur Anwendung. Stimulierende Verfahren \n* aktive Impfung und \n* die Gabe von Immunstimulantien zur Aktivierung eines geschw\u00E4chten Immunsystems im Rahmen einer aktiven unspezifischen Immuntherapie bei Tumorerkrankungen (siehe Hauptartikel Krebsimmuntherapie)Supprimierende Verfahren (Gabe von Immunsuppressiva) \n* bei Autoimmunkrankheiten, \n* nach Organtransplantation, \n* bei Allergien (Anaphylaxie) undSubstituierende Verfahren \n* passive Impfung mit Immunglobulinen (Tetanus, Botulismus, Rhesus-Inkompatibilit\u00E4t u. v. m.) \n* Gabe von Immunglobulinen bei erworbenem oder angeborenem Mangel an Immunglobulinen (sog. Immunglobulinmangel mit daraus resultierender Infektionsanf\u00E4lligkeit)Gabe monoklonaler Antik\u00F6rper bei \n* \n* Morbus Crohn (Infliximab), \n* PTCA (Thrombozytenaggregationshemmer Abciximab) oder \n* spezifische Immuntherapien bei Tumorerkrankungen, bei Kombination der Antik\u00F6rper mit Toxinen (z. B. Saporin) als Immuntoxine bezeichnet.Modulierende Verfahren \n* Hyposensibilisierung bei Allergien \n* Immunadsorption zur Entfernung von Autoantik\u00F6rpern und Immunkomplexen bei Autoimmunerkrankungen oder antik\u00F6rpervermittelten Transplantatabsto\u00DFungen"@de . . . "\u0397 \u0391\u03BD\u03BF\u03C3\u03BF\u03B8\u03B5\u03C1\u03B1\u03C0\u03B5\u03AF\u03B1 \u03B5\u03AF\u03BD\u03B1\u03B9 \u03B9\u03B1\u03C4\u03C1\u03B9\u03BA\u03AE \u03B8\u03B5\u03C1\u03B1\u03C0\u03B5\u03C5\u03C4\u03B9\u03BA\u03AE \u03BC\u03AD\u03B8\u03BF\u03B4\u03BF\u03C2 \u03C0\u03BF\u03C5 \u03B2\u03B1\u03C3\u03AF\u03B6\u03B5\u03C4\u03B1\u03B9 \u03C3\u03B5 \u03B4\u03B9\u03AD\u03B3\u03B5\u03C1\u03C3\u03B7 \u03C4\u03BF\u03C5 \u03B1\u03BD\u03BF\u03C3\u03BF\u03C0\u03BF\u03B9\u03B7\u03C4\u03B9\u03BA\u03BF\u03CD \u03C3\u03C5\u03C3\u03C4\u03AE\u03BC\u03B1\u03C4\u03BF\u03C2 \u03C4\u03BF\u03C5 \u03B1\u03BD\u03B8\u03C1\u03CE\u03C0\u03B9\u03BD\u03BF\u03C5 \u03BF\u03C1\u03B3\u03B1\u03BD\u03B9\u03C3\u03BC\u03BF\u03CD \u03B7 \u03BF\u03C0\u03BF\u03AF\u03B1 \u03B5\u03C6\u03B1\u03C1\u03BC\u03CC\u03B6\u03B5\u03C4\u03B1\u03B9 \u03BA\u03C5\u03C1\u03AF\u03C9\u03C2 \u03C3\u03C4\u03B7 \u03B8\u03B5\u03C1\u03B1\u03C0\u03B5\u03AF\u03B1 \u03C4\u03BF\u03C5 \u03BA\u03B1\u03C1\u03BA\u03AF\u03BD\u03BF\u03C5 (\u03BC\u03CC\u03BD\u03B7 \u03C4\u03B7\u03C2 \u03AE \u03C3\u03B5 \u03C3\u03C5\u03BD\u03B4\u03C5\u03B1\u03C3\u03BC\u03CC \u03BC\u03B5 \u03C7\u03B7\u03BC\u03B5\u03B9\u03BF\u03B8\u03B5\u03C1\u03B1\u03C0\u03B5\u03AF\u03B1) \u03B1\u03BB\u03BB\u03AC \u03BA\u03B1\u03B9 \u03C3\u03B5 \u03AC\u03BB\u03BB\u03B5\u03C2 \u03C0\u03B5\u03C1\u03B9\u03C0\u03C4\u03CE\u03C3\u03B5\u03B9\u03C2, \u03CC\u03C0\u03C9\u03C2 \u03B3\u03B9\u03B1 \u03C4\u03B7\u03BD \u03C0\u03C1\u03CC\u03BB\u03B7\u03C8\u03B7 \u03B1\u03BB\u03BB\u03B5\u03C1\u03B3\u03B9\u03CE\u03BD. \u039A\u03B1\u03C4\u03AC \u03C4\u03BF \u03C0\u03B1\u03C1\u03B5\u03BB\u03B8\u03CC\u03BD \u03B2\u03C1\u03B9\u03C3\u03BA\u03CC\u03C4\u03B1\u03BD \u03C3\u03B5 \u03C0\u03B5\u03B9\u03C1\u03B1\u03BC\u03B1\u03C4\u03B9\u03BA\u03CC \u03C3\u03C4\u03AC\u03B4\u03B9\u03BF, \u03B1\u03BB\u03BB\u03AC \u03C0\u03C1\u03CC\u03C3\u03C6\u03B1\u03C4\u03B1 \u03AD\u03C7\u03B5\u03B9 \u03B1\u03C0\u03BF\u03B4\u03B5\u03B9\u03C7\u03B8\u03B5\u03AF \u03B1\u03C0\u03CC \u03C3\u03C7\u03B5\u03C4\u03B9\u03BA\u03AD\u03C2 \u03BC\u03B5\u03BB\u03AD\u03C4\u03B5\u03C2 \u03B7 \u03B1\u03C0\u03BF\u03C4\u03B5\u03BB\u03B5\u03C3\u03BC\u03B1\u03C4\u03B9\u03BA\u03CC\u03C4\u03B7\u03C4\u03AC \u03C4\u03B7\u03C2. \u03A9\u03C3\u03C4\u03CC\u03C3\u03BF, \u03B1\u03C0\u03BF\u03C4\u03B5\u03BB\u03B5\u03AF \u03B4\u03CD\u03C3\u03BA\u03BF\u03BB\u03B7 \u03BA\u03B1\u03B9 \u03B5\u03C0\u03AF\u03C0\u03BF\u03BD\u03B7 \u03B8\u03B5\u03C1\u03B1\u03C0\u03B5\u03AF\u03B1 \u03B3\u03B9\u03B1 \u03C4\u03BF\u03BD \u03B1\u03C3\u03B8\u03B5\u03BD\u03AE, \u03B4\u03B5\u03BD \u03B5\u03C6\u03B1\u03C1\u03BC\u03CC\u03B6\u03B5\u03C4\u03B1\u03B9 \u03C3\u03B5 \u03CC\u03BB\u03BF\u03C5\u03C2 \u03C4\u03BF\u03C5\u03C2 \u03BA\u03B1\u03C1\u03BA\u03B9\u03BD\u03BF\u03C0\u03B1\u03B8\u03B5\u03AF\u03C2, \u03B5\u03BD\u03CE \u03C0\u03C1\u03BF\u03BA\u03B1\u03BB\u03B5\u03AF, \u03C3\u03B5 \u03BF\u03C1\u03B9\u03C3\u03BC\u03AD\u03BD\u03B5\u03C2 \u03C0\u03B5\u03C1\u03B9\u03C0\u03C4\u03CE\u03C3\u03B5\u03B9\u03C2, \u03C0\u03AC\u03C1\u03B1 \u03C0\u03BF\u03BB\u03BB\u03AD\u03C2 \u03C0\u03B1\u03C1\u03B5\u03BD\u03AD\u03C1\u03B3\u03B5\u03B9\u03B5\u03C2 \u03AE \u03B1\u03BA\u03CC\u03BC\u03B7 \u03BA\u03B1\u03B9 \u03B5\u03C0\u03B9\u03C0\u03BB\u03BF\u03BA\u03AD\u03C2, \u03CC\u03C0\u03C9\u03C2 \u03C4\u03B1 \u03B1\u03C5\u03C4\u03BF\u03AC\u03BD\u03BF\u03C3\u03B1 \u03BD\u03BF\u03C3\u03AE\u03BC\u03B1\u03C4\u03B1. \u03A3\u03CD\u03BC\u03C6\u03C9\u03BD\u03B1 \u03BC\u03B5 \u03C4\u03BF \u03BC\u03B7\u03C7\u03B1\u03BD\u03B9\u03C3\u03BC\u03CC \u03C4\u03B7\u03C2 \u03B1\u03BD\u03BF\u03C3\u03BF\u03B8\u03B5\u03C1\u03B1\u03C0\u03B5\u03AF\u03B1\u03C2, \u03B1\u03C5\u03C4\u03AE \u03BF\u03B4\u03B7\u03B3\u03B5\u03AF \u03C4\u03B1 \u03BB\u03B5\u03C5\u03BA\u03AC \u03B1\u03B9\u03BC\u03BF\u03C3\u03C6\u03B1\u03AF\u03C1\u03B9\u03B1 \u03BD\u03B1 \u03C3\u03C4\u03C1\u03B1\u03C6\u03BF\u03CD\u03BD \u03C0\u03C1\u03BF\u03C2 \u03C4\u03B1 \u03BA\u03B1\u03C1\u03BA\u03B9\u03BD\u03B9\u03BA\u03AC \u03BA\u03CD\u03C4\u03C4\u03B1\u03C1\u03B1 \u03C4\u03BF\u03C5 \u03BA\u03B1\u03BA\u03BF\u03AE\u03B8\u03BF\u03C5\u03C2 \u03CC\u03B3\u03BA\u03BF\u03C5 \u03BA\u03B1\u03B9 \u03BD\u03B1 \u03C4\u03B1 \u03BA\u03B1\u03C4\u03B1\u03C3\u03C4\u03C1\u03AD\u03C8\u03BF\u03C5\u03BD."@el . . . . "Imunoterapi adalah pengobatan penyakit dengan mengaktifkan atau menekan sistem imun. Imunoterapi yang dirancang untuk memperoleh atau memperkuat respons imun diklasifikasikan sebagai imunoterapi aktivasi, sedangkan imunoterapi yang mengurangi atau menekan diklasifikasikan sebagai imunoterapi penekan. Dalam beberapa tahun terakhir, imunoterapi telah menjadi sangat menarik bagi para peneliti, dokter dan perusahaan farmasi, terutama dalam prospeknya untuk mengobati berbagai bentuk kanker. Regimen imunomodulator sering memiliki efek samping yang lebih sedikit daripada obat yang ada, termasuk lebih sedikit potensi untuk menciptakan resistensi ketika mengobati penyakit mikrob. Imunoterapi berbasis sel efektif untuk beberapa kanker. Sel-sel efektor imun seperti limfosit, makrofag, sel dendritik, sel pembunuh alami (sel NK), limfosit T pembunuh (CTL) bekerja bersama untuk mempertahankan tubuh terhadap kanker dengan menargetkan antigen abnormal yang diekspresikan pada permukaan sel tumor. Terapi seperti granulocyte colony-stimulating factor (G-CSF), interferon, imiquimod, dan fraksi membran seluler dari bakteri telah disetujui untuk penggunaan medis. Sedangkan lainnya sedang dalam uji klinis dan praklinis termasuk IL-2, IL-7, IL-12, berbagai kemokin, sitosin fosfat-guanosin sintetis (CpG) oligodeoksinukleotida dan glukan."@in . . . . . . . . . . . . . . . . . . . . . . . "Immunoterapia \u2013 zbi\u00F3r metod polegaj\u0105cych na modyfikacji czynno\u015Bci uk\u0142adu odporno\u015Bciowego. Obejmuje: \n* immunosupresj\u0119 \n* \n* Stosuje si\u0119 je mi\u0119dzy innymi w leczeniu nowotwor\u00F3w, chor\u00F3b autoimmunologicznych i transplantologii. Immunoterapi\u0119 dzieli si\u0119 na: \n* lokaln\u0105 (dotyczy jednej cz\u0119\u015Bci cia\u0142a) \n* ca\u0142o\u015Bciow\u0105 (dotyczy ca\u0142ego cia\u0142a; np. zastosowanie interferonu-alfa oraz genu interleukin-2 IL-2) lub:"@pl . "\u514D\u75AB\u7642\u6CD5\uFF08\u3081\u3093\u3048\u304D\u308A\u3087\u3046\u307B\u3046\u3001\u82F1: Immunotherapy\uFF09\u306F\u3001\u300C\u514D\u75AB\u5FDC\u7B54\u3092\u8A98\u5C0E\u3001\u5897\u5F37\u3001\u307E\u305F\u306F\u6291\u5236\u3059\u308B\u3053\u3068\u306B\u3088\u308B\u75BE\u60A3\u306E\u6CBB\u7642\u300D\u3067\u3042\u308B\u3002\u514D\u75AB\u7642\u6CD5\u306F\u3001\u514D\u75AB\u5FDC\u7B54\u3092\u8A98\u767A\u307E\u305F\u306F\u5897\u5E45\u3059\u308B\u514D\u75AB\u7642\u6CD5\u3001\u514D\u75AB\u5FDC\u7B54\u3092\u6291\u5236\u3059\u308B\u514D\u75AB\u7642\u6CD5\u306B\u5206\u985E\u3067\u304D\u308B\u3002 \u514D\u75AB\u7642\u6CD5\u306B\u4F7F\u3046\u85AC\u306F\u3001\u75C5\u539F\u4F53\u306B\u3088\u308B\u611F\u67D3\u3092\u6CBB\u7642\u3059\u308B\u969B\u306B\u4F7F\u7528\u3057\u3066\u3082\u3001\u75C5\u539F\u4F53\u304C\u8010\u6027\u3092\u5F97\u308B\u53EF\u80FD\u6027\u304C\u4F4E\u3044\u306A\u3069\u3001\u65E2\u5B58\u306E\u85AC\u7269\u3088\u308A\u3082\u526F\u4F5C\u7528\u304C\u5C11\u306A\u3044\u3053\u3068\u304C\u591A\u3044\u3002 \u7D30\u80DE\u30D9\u30FC\u30B9\u306E\u514D\u75AB\u7642\u6CD5\u306F\u3001\u3044\u304F\u3064\u304B\u306E\u304C\u3093\u306B\u5BFE\u3057\u3066\u6709\u52B9\u3067\u3042\u308B\u3002\u30EA\u30F3\u30D1\u7403\u3001\u30DE\u30AF\u30ED\u30D5\u30A1\u30FC\u30B8\u3001\u6A39\u72B6\u7D30\u80DE\u3001\u30CA\u30C1\u30E5\u30E9\u30EB\u30AD\u30E9\u30FC\u7D30\u80DE\uFF08NK\u7D30\u80DE\uFF09\u3001\u7D30\u80DE\u50B7\u5BB3\u6027T\u30EA\u30F3\u30D1\u7403\uFF08CTL\uFF09\u306A\u3069\u306E\u514D\u75AB\u7D30\u80DE\u306F\u3001\u816B\u760D\u7D30\u80DE\u306E\u8868\u9762\u4E0A\u306B\u767A\u73FE\u3059\u308B\u7570\u5E38\u6297\u539F\u3092\u6A19\u7684\u306B\u3057\u3066\u304C\u3093\u7D30\u80DE\u3092\u6392\u9664\u3059\u308B\u3002\u9846\u7C92\u7403\u30B3\u30ED\u30CB\u30FC\u523A\u6FC0\u56E0\u5B50\uFF08G-CSF\uFF09\u3001\u30A4\u30F3\u30BF\u30FC\u30D5\u30A7\u30ED\u30F3\u3001\u30A4\u30DF\u30AD\u30E2\u30C9\u3001\u304A\u3088\u3073\u7D30\u83CC\u7531\u6765\u306E\u7D30\u80DE\u819C\u753B\u5206\u306A\u3069\u3092\u4F7F\u3063\u305F\u6CBB\u7642\u6CD5\u306F\u3001\u533B\u7642\u7528\u9014\u3067\u8A8D\u53EF\u3055\u308C\u3066\u3044\u308B\u3002 IL-2\u3001IL-7\u3001IL-12\u3001\u7A2E\u3005\u306E\u30B1\u30E2\u30AB\u30A4\u30F3\u3001\u5408\u6210\u30B7\u30C8\u30B7\u30F3\u30EA\u30F3\u9178\u30B0\u30A2\u30CE\u30B7\u30F3\uFF08CpG\uFF09\u30AA\u30EA\u30B4\u30C7\u30AA\u30AD\u30B7\u30CC\u30AF\u30EC\u30AA\u30C1\u30C9\u304A\u3088\u3073\u30B0\u30EB\u30AB\u30F3\u3092\u542B\u3080\u4ED6\u306E\u3082\u306E\u306F\u3001\u81E8\u5E8A\u8A66\u9A13\u3001\u3042\u308B\u3044\u306F\u524D\u81E8\u5E8A\u6BB5\u968E\u3067\u3042\u308B\u3002"@ja . "\u0406\u043C\u0443\u043D\u043E\u0442\u0435\u0440\u0430\u043F\u0456\u0301\u044F \u2014 \u0440\u043E\u0437\u0434\u0456\u043B \u043F\u0440\u0430\u043A\u0442\u0438\u0447\u043D\u043E\u0457 \u0456\u043C\u0443\u043D\u043E\u043B\u043E\u0433\u0456\u0457, \u0437\u0430\u0432\u0434\u0430\u043D\u043D\u044F\u043C \u044F\u043A\u043E\u0433\u043E \u0454 \u043B\u0456\u043A\u0443\u0432\u0430\u043D\u043D\u044F \u0456\u043C\u0443\u043D\u043E\u0431\u0456\u043E\u043B\u043E\u0433\u0456\u0447\u043D\u0438\u043C\u0438 \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442\u0430\u043C\u0438 \u2014 \u0432\u0430\u043A\u0446\u0438\u043D\u0430\u043C\u0438, \u0441\u0438\u0440\u043E\u0432\u0430\u0442\u043A\u0430\u043C\u0438, \u0456\u043D\u0442\u0435\u0440\u0444\u0435\u0440\u043E\u043D\u0430\u043C\u0438, \u0431\u0430\u043A\u0442\u0435\u0440\u0456\u043E\u0444\u0430\u0433\u0430\u043C\u0438, \u0430\u043B\u0435\u0440\u0433\u0435\u043D\u0430\u043C\u0438 \u0442\u0430 \u0456\u043D\u0448\u0438\u043C. \u0412\u0456\u0434\u043D\u043E\u0441\u043D\u043E \u0435\u0442\u0456\u043E\u043B\u043E\u0433\u0456\u0447\u043D\u043E\u0433\u043E \u0447\u0438\u043D\u043D\u0438\u043A\u0430 \u0432\u0438\u0434\u0456\u043B\u044F\u044E\u0442\u044C \u0456\u043C\u0443\u043D\u043E\u0442\u0435\u0440\u0430\u043F\u0456\u044E: \n* \u0441\u043F\u0435\u0446\u0438\u0444\u0456\u0447\u043D\u0443 \n* \u043D\u0435\u0441\u043F\u0435\u0446\u0438\u0444\u0456\u0447\u043D\u0443 \u0412\u0456\u0434\u043D\u043E\u0441\u043D\u043E \u043E\u0440\u0433\u0430\u043D\u0456\u0437\u043C\u0443 \u043F\u0430\u0446\u0456\u0454\u043D\u0442\u0430: \n* \u0430\u043A\u0442\u0438\u0432\u043D\u0443 \n* \u043F\u0430\u0441\u0438\u0432\u043D\u0443 \u041F\u0435\u0440\u0435\u0432\u0430\u0433\u043E\u044E \u0456\u043C\u0443\u043D\u043E\u0442\u0435\u0440\u0430\u043F\u0456\u0457 \u0454 \u043C\u043E\u0436\u043B\u0438\u0432\u0456\u0441\u0442\u044C \u043F\u0440\u043E\u0432\u0435\u0434\u0435\u043D\u043D\u044F \u043B\u0456\u043A\u0443\u0432\u0430\u043D\u043D\u044F \u0437 \u0443\u0440\u0430\u0445\u0443\u0432\u0430\u043D\u043D\u044F\u043C \u043A\u043E\u043D\u043A\u0440\u0435\u0442\u043D\u043E\u0433\u043E (\u0441\u043F\u0435\u0446\u0438\u0444\u0456\u0447\u043D\u043E\u0433\u043E) \u0435\u0442\u0456\u043E\u043B\u043E\u0433\u0456\u0447\u043D\u043E\u0433\u043E \u0447\u0438\u043D\u043D\u0438\u043A\u0430 \u0437\u0430\u0445\u0432\u043E\u0440\u044E\u0432\u0430\u043D\u043D\u044F (\u0456\u043D\u0444\u0435\u043A\u0446\u0456\u0439\u043D\u043E\u0433\u043E, \u0430\u043B\u0435\u0440\u0433\u0456\u0447\u043D\u043E\u0433\u043E). \u0422\u043E\u043C\u0443 \u043D\u0430\u0439\u0447\u0430\u0441\u0442\u0456\u0448\u0435 \u0432\u0438\u043A\u043E\u0440\u0438\u0441\u0442\u043E\u0432\u0443\u044E\u0442\u044C \u0441\u0430\u043C\u0435 \u0441\u043F\u0435\u0446\u0438\u0444\u0456\u0447\u043D\u0443 \u0456\u043C\u0443\u043D\u043E\u0442\u0435\u0440\u0430\u043F\u0456\u044E."@uk . . . . "La immunoter\u00E0pia \u00E9s un tractament m\u00E8dic que consisteix a administrar subst\u00E0ncies que estimulin el sistema immunitari de l'organisme a fi de lluitar contra diferents malalties, en particular certs c\u00E0ncers hematol\u00F2gics, les malalties degeneratives i les malalties autoimmunit\u00E0ries sist\u00E8miques. Per extensi\u00F3, la immunoter\u00E0pia designa igualment a una ter\u00E0pia que utilitzi prote\u00EFnes produ\u00EFdes per les c\u00E8l\u00B7lules del sistema immunitari, en particular les immunoglobulines, sense que l'objectiu d'aquesta ter\u00E0pia sigui necess\u00E0riament l'estimulaci\u00F3 de la immunitat."@ca . . . . . . "\u0397 \u0391\u03BD\u03BF\u03C3\u03BF\u03B8\u03B5\u03C1\u03B1\u03C0\u03B5\u03AF\u03B1 \u03B5\u03AF\u03BD\u03B1\u03B9 \u03B9\u03B1\u03C4\u03C1\u03B9\u03BA\u03AE \u03B8\u03B5\u03C1\u03B1\u03C0\u03B5\u03C5\u03C4\u03B9\u03BA\u03AE \u03BC\u03AD\u03B8\u03BF\u03B4\u03BF\u03C2 \u03C0\u03BF\u03C5 \u03B2\u03B1\u03C3\u03AF\u03B6\u03B5\u03C4\u03B1\u03B9 \u03C3\u03B5 \u03B4\u03B9\u03AD\u03B3\u03B5\u03C1\u03C3\u03B7 \u03C4\u03BF\u03C5 \u03B1\u03BD\u03BF\u03C3\u03BF\u03C0\u03BF\u03B9\u03B7\u03C4\u03B9\u03BA\u03BF\u03CD \u03C3\u03C5\u03C3\u03C4\u03AE\u03BC\u03B1\u03C4\u03BF\u03C2 \u03C4\u03BF\u03C5 \u03B1\u03BD\u03B8\u03C1\u03CE\u03C0\u03B9\u03BD\u03BF\u03C5 \u03BF\u03C1\u03B3\u03B1\u03BD\u03B9\u03C3\u03BC\u03BF\u03CD \u03B7 \u03BF\u03C0\u03BF\u03AF\u03B1 \u03B5\u03C6\u03B1\u03C1\u03BC\u03CC\u03B6\u03B5\u03C4\u03B1\u03B9 \u03BA\u03C5\u03C1\u03AF\u03C9\u03C2 \u03C3\u03C4\u03B7 \u03B8\u03B5\u03C1\u03B1\u03C0\u03B5\u03AF\u03B1 \u03C4\u03BF\u03C5 \u03BA\u03B1\u03C1\u03BA\u03AF\u03BD\u03BF\u03C5 (\u03BC\u03CC\u03BD\u03B7 \u03C4\u03B7\u03C2 \u03AE \u03C3\u03B5 \u03C3\u03C5\u03BD\u03B4\u03C5\u03B1\u03C3\u03BC\u03CC \u03BC\u03B5 \u03C7\u03B7\u03BC\u03B5\u03B9\u03BF\u03B8\u03B5\u03C1\u03B1\u03C0\u03B5\u03AF\u03B1) \u03B1\u03BB\u03BB\u03AC \u03BA\u03B1\u03B9 \u03C3\u03B5 \u03AC\u03BB\u03BB\u03B5\u03C2 \u03C0\u03B5\u03C1\u03B9\u03C0\u03C4\u03CE\u03C3\u03B5\u03B9\u03C2, \u03CC\u03C0\u03C9\u03C2 \u03B3\u03B9\u03B1 \u03C4\u03B7\u03BD \u03C0\u03C1\u03CC\u03BB\u03B7\u03C8\u03B7 \u03B1\u03BB\u03BB\u03B5\u03C1\u03B3\u03B9\u03CE\u03BD. \u039A\u03B1\u03C4\u03AC \u03C4\u03BF \u03C0\u03B1\u03C1\u03B5\u03BB\u03B8\u03CC\u03BD \u03B2\u03C1\u03B9\u03C3\u03BA\u03CC\u03C4\u03B1\u03BD \u03C3\u03B5 \u03C0\u03B5\u03B9\u03C1\u03B1\u03BC\u03B1\u03C4\u03B9\u03BA\u03CC \u03C3\u03C4\u03AC\u03B4\u03B9\u03BF, \u03B1\u03BB\u03BB\u03AC \u03C0\u03C1\u03CC\u03C3\u03C6\u03B1\u03C4\u03B1 \u03AD\u03C7\u03B5\u03B9 \u03B1\u03C0\u03BF\u03B4\u03B5\u03B9\u03C7\u03B8\u03B5\u03AF \u03B1\u03C0\u03CC \u03C3\u03C7\u03B5\u03C4\u03B9\u03BA\u03AD\u03C2 \u03BC\u03B5\u03BB\u03AD\u03C4\u03B5\u03C2 \u03B7 \u03B1\u03C0\u03BF\u03C4\u03B5\u03BB\u03B5\u03C3\u03BC\u03B1\u03C4\u03B9\u03BA\u03CC\u03C4\u03B7\u03C4\u03AC \u03C4\u03B7\u03C2. \u03A9\u03C3\u03C4\u03CC\u03C3\u03BF, \u03B1\u03C0\u03BF\u03C4\u03B5\u03BB\u03B5\u03AF \u03B4\u03CD\u03C3\u03BA\u03BF\u03BB\u03B7 \u03BA\u03B1\u03B9 \u03B5\u03C0\u03AF\u03C0\u03BF\u03BD\u03B7 \u03B8\u03B5\u03C1\u03B1\u03C0\u03B5\u03AF\u03B1 \u03B3\u03B9\u03B1 \u03C4\u03BF\u03BD \u03B1\u03C3\u03B8\u03B5\u03BD\u03AE, \u03B4\u03B5\u03BD \u03B5\u03C6\u03B1\u03C1\u03BC\u03CC\u03B6\u03B5\u03C4\u03B1\u03B9 \u03C3\u03B5 \u03CC\u03BB\u03BF\u03C5\u03C2 \u03C4\u03BF\u03C5\u03C2 \u03BA\u03B1\u03C1\u03BA\u03B9\u03BD\u03BF\u03C0\u03B1\u03B8\u03B5\u03AF\u03C2, \u03B5\u03BD\u03CE \u03C0\u03C1\u03BF\u03BA\u03B1\u03BB\u03B5\u03AF, \u03C3\u03B5 \u03BF\u03C1\u03B9\u03C3\u03BC\u03AD\u03BD\u03B5\u03C2 \u03C0\u03B5\u03C1\u03B9\u03C0\u03C4\u03CE\u03C3\u03B5\u03B9\u03C2, \u03C0\u03AC\u03C1\u03B1 \u03C0\u03BF\u03BB\u03BB\u03AD\u03C2 \u03C0\u03B1\u03C1\u03B5\u03BD\u03AD\u03C1\u03B3\u03B5\u03B9\u03B5\u03C2 \u03AE \u03B1\u03BA\u03CC\u03BC\u03B7 \u03BA\u03B1\u03B9 \u03B5\u03C0\u03B9\u03C0\u03BB\u03BF\u03BA\u03AD\u03C2, \u03CC\u03C0\u03C9\u03C2 \u03C4\u03B1 \u03B1\u03C5\u03C4\u03BF\u03AC\u03BD\u03BF\u03C3\u03B1 \u03BD\u03BF\u03C3\u03AE\u03BC\u03B1\u03C4\u03B1. \u03A3\u03CD\u03BC\u03C6\u03C9\u03BD\u03B1 \u03BC\u03B5 \u03C4\u03BF \u03BC\u03B7\u03C7\u03B1\u03BD\u03B9\u03C3\u03BC\u03CC \u03C4\u03B7\u03C2 \u03B1\u03BD\u03BF\u03C3\u03BF\u03B8\u03B5\u03C1\u03B1\u03C0\u03B5\u03AF\u03B1\u03C2, \u03B1\u03C5\u03C4\u03AE \u03BF\u03B4\u03B7\u03B3\u03B5\u03AF \u03C4\u03B1 \u03BB\u03B5\u03C5\u03BA\u03AC \u03B1\u03B9\u03BC\u03BF\u03C3\u03C6\u03B1\u03AF\u03C1\u03B9\u03B1 \u03BD\u03B1 \u03C3\u03C4\u03C1\u03B1\u03C6\u03BF\u03CD\u03BD \u03C0\u03C1\u03BF\u03C2 \u03C4\u03B1 \u03BA\u03B1\u03C1\u03BA\u03B9\u03BD\u03B9\u03BA\u03AC \u03BA\u03CD\u03C4\u03C4\u03B1\u03C1\u03B1 \u03C4\u03BF\u03C5 \u03BA\u03B1\u03BA\u03BF\u03AE\u03B8\u03BF\u03C5\u03C2 \u03CC\u03B3\u03BA\u03BF\u03C5 \u03BA\u03B1\u03B9 \u03BD\u03B1 \u03C4\u03B1 \u03BA\u03B1\u03C4\u03B1\u03C3\u03C4\u03C1\u03AD\u03C8\u03BF\u03C5\u03BD."@el . . . "L'immunoth\u00E9rapie consiste \u00E0 administrer des substances stimulant les d\u00E9fenses immunitaires du malade contre des infections, certains cancers h\u00E9matologiques (autrement dit, du sang), des maladies d\u00E9g\u00E9n\u00E9ratives ou auto-immunes. Ceci inclut les th\u00E9rapies utilisant des prot\u00E9ines (anticorps) produites par les cellules du syst\u00E8me immunitaire, en particulier les immunoglobulines, sans que l'objectif de cette th\u00E9rapie ne soit n\u00E9cessairement la stimulation de l'immunit\u00E9. On distingue l'immunoth\u00E9rapie locale (rare) et l'immunoth\u00E9rapie g\u00E9n\u00E9rale (beaucoup plus fr\u00E9quente). Des anc\u00EAtres de l'immunoth\u00E9rapie contemporaine sont la \u00AB th\u00E9rapie s\u00E9rique \u00BB et l'immunoth\u00E9rapie allerg\u00E9nique mise au point par Leonard Noon et John Freeman en 1911. Les essais modernes d'immunoth\u00E9rapie remontent aux ann\u00E9es 1970, bas\u00E9s sur des . Depuis, d'autres mol\u00E9cules sont arriv\u00E9es sur le devant de la sc\u00E8ne, telles les immunoglobulines monoclonales, et moindrement les interf\u00E9rons, les interleukines et les inhibiteurs de point de contr\u00F4le."@fr . "La inmunoterapia, bioterapia, terapia biol\u00F3gica, terapia modificadora de la respuesta biol\u00F3gica o terapia MRB, en medicina, se refiere al conjunto de estrategias de tratamiento para estimular o reponer el sistema inmunitario frente al c\u00E1ncer, infecciones u otras enfermedades as\u00ED como para aminorar los efectos secundarios de tratamientos muy agresivos usados contra el c\u00E1ncer. El objetivo puede ser profil\u00E1ctico (preventivo) o terap\u00E9utico (curativo o de mantenimiento). Dentro de los tratamientos biol\u00F3gicos est\u00E1n los anticuerpos monoclonales, las vacunas y los denominados factores de crecimiento.\u200B Las mol\u00E9culas activas implicadas en la inmunoterapia se denominan inmunomoduladores. La mayor parte son citoquinas y algunas de ellas, como por ejemplo el factor estimulante de colonias de granulocitos (G-CSF, ) o el interfer\u00F3n, ya est\u00E1n siendo usados en cl\u00EDnicas. Otros tipos de citoquinas, como las 1, 2, 6, 8 o el factor de necrosis tumoral (TNF-\u03B1), se est\u00E1n utilizando en numerosos ensayos cl\u00EDnicos y otros estudios preliminares para un futuro uso en inmunoterapia."@es . . . . . "Immuntherapie"@de . "The diagram above represents the process of chimeric antigen receptor T-cell therapy , this is a method of immunotherapy, which is a growing practice in the treatment of cancer. The final result should be a production of equipped T-cells that can recognize and fight the infected cancer cells in the body."@en . . . "\uBA74\uC5ED\uC694\uBC95"@ko . "226533"^^ . "\u514D\u75AB\u6CBB\u7597\uFF08\u82F1\u8A9E\uFF1AImmunotherapy\uFF09\uFF0C\u662F\u6307\u901A\u8FC7\u8BF1\u5BFC\u3001\u589E\u5F3A\u6216\u6291\u5236\u514D\u75AB\u53CD\u5E94\u7684\u75BE\u75C5\u6CBB\u7597\u65B9\u6CD5\u3002\u5176\u4E2D\u65E8\u5728\u5F15\u8D77\u6216\u589E\u5F3A\u514D\u75AB\u53CD\u5E94\u7684\u514D\u75AB\u7597\u6CD5\uFF0C\u79F0\u4E3A\u6FC0\u6D3B\u514D\u75AB\u7597\u6CD5\uFF08activation immunotherapies\uFF09\uFF0C\u800C\u51CF\u5C11\u6216\u6291\u5236\u514D\u75AB\u53CD\u5E94\u5219\u662F\u6291\u5236\u514D\u75AB\u7597\u6CD5\uFF08suppression immunotherapies\uFF09\u3002 \u514D\u75AB\u7597\u6CD5\u5F80\u5F80\u6BD4\u73B0\u6709\u836F\u7269\u7684\u526F\u4F5C\u7528\u5C11\uFF0C\u5305\u62EC\u51CF\u5C11\u5BF9\u5FAE\u751F\u7269\u75BE\u75C5\u7684\u6297\u836F\u6027\u53CD\u5E94\u3002 \u57FA\u4E8E\u7EC6\u80DE\u7684\u514D\u75AB\u7597\u6CD5\u5BF9\u4E00\u4E9B\u764C\u75C7\u6709\u6548\u3002\u514D\u75AB\u6548\u5E94\u7EC6\u80DE\u5982\u6DCB\u5DF4\u7EC6\u80DE\u3001\u5DE8\u566C\u7EC6\u80DE\u3001\u6811\u7A81\u72B6\u7EC6\u80DE\u3001\u81EA\u7136\u6740\u4F24\u7EC6\u80DE\uFF08NK\u7EC6\u80DE\uFF09\uFF0C\u7EC6\u80DE\u6BD2\u6027T\u6DCB\u5DF4\u7EC6\u80DE\uFF08CTL\uFF09\u7B49\uFF0C\u901A\u8FC7\u9488\u5BF9\u80BF\u7624\u7EC6\u80DE\u8868\u9762\u7684\u5F02\u5E38\u6297\u539F\uFF0C\u6765\u5171\u540C\u5E2E\u52A9\u8EAB\u4F53\u62B5\u5FA1\u764C\u75C7\u3002 \uFF08G-CSF\uFF09\u3001\u5E72\u6270\u7D20\u3001\u4E0E\u7EC6\u83CC\u7EC6\u80DE\u819C\u7EC4\u5206\u7B49\u7597\u6CD5\uFF0C\u5DF2\u7ECF\u8BB8\u53EF\u8FDB\u5165\u4E34\u5E8A\u6CBB\u7597\u3002\u5176\u4ED6\u7814\u7A76\u6709\u767D\u7EC6\u80DE\u4ECB\u7D20-2\u3001\u3001\u3001\u5404\u79CD\u8D8B\u5316\u56E0\u5B50\u3001\u4EBA\u5DE5\u5408\u6210\u7684CpG\u5BE1\u8131\u6C27\u6838\u82F7\u9178\u548C\u8461\u805A\u7CD6\u7B49\uFF0C\u8FD9\u4E9B\u5747\u5DF2\u8FDB\u5165\u4E34\u5E8A\u548C\u4E34\u5E8A\u524D\u7814\u7A76\u3002"@zh . . . . . . "La immunoter\u00E0pia \u00E9s un tractament m\u00E8dic que consisteix a administrar subst\u00E0ncies que estimulin el sistema immunitari de l'organisme a fi de lluitar contra diferents malalties, en particular certs c\u00E0ncers hematol\u00F2gics, les malalties degeneratives i les malalties autoimmunit\u00E0ries sist\u00E8miques. Per extensi\u00F3, la immunoter\u00E0pia designa igualment a una ter\u00E0pia que utilitzi prote\u00EFnes produ\u00EFdes per les c\u00E8l\u00B7lules del sistema immunitari, en particular les immunoglobulines, sense que l'objectiu d'aquesta ter\u00E0pia sigui necess\u00E0riament l'estimulaci\u00F3 de la immunitat. Els primers assaigs d'immunoter\u00E0pia es remunten a la d\u00E8cada de 1970 i utilitzaven els anticossos policlonals. Actualment s'utilitzen diverses mol\u00E8cules: en primer lloc les immunoglobulines monoclonals, els interferons i les interleuquines."@ca . . . "Biologick\u00E1 l\u00E9\u010Dba nebo imunoterapie, \u0159\u00EDd\u010D. c\u00EDlen\u00E1 l\u00E9\u010Dba, vyu\u017E\u00EDv\u00E1 imunitu organismu a jej\u00ED zeslaben\u00ED nebo zes\u00EDlen\u00ED k l\u00E9\u010Db\u011B nemoc\u00ED. Imunoefektorov\u00E9 bu\u0148ky typu lymfocyt\u016F, makrof\u00E1g\u016F, dendritick\u00FDch bun\u011Bk,NK bu\u0148ky, T-lymfocyty mohou \u00FA\u010Dinn\u011B bojovat proti rakovin\u011B \u010Di n\u011Bkter\u00FDm autoimunitn\u00EDm chorob\u00E1m d\u00EDky tomu, \u017Ee jsou l\u00E9pe zn\u00E1m\u00E9 struktury a pochody na povrchu i uvnit\u0159 bu\u0148ky. Terapie granulocyte colony-stimulating factor (G-CSF), interferon\u016F, imikvimod\u016F a bun\u011B\u010Dn\u00E9 membr\u00E1nov\u00E9 frakce bakteri\u00ED jsou povoleny pro medic\u00EDnsk\u00E9 pou\u017Eit\u00ED. Dal\u0161\u00ED typy terapi\u00ED IL-2, IL-7, IL-12, chemokiny, (CpG) oligodeoxynukleotidy a glukany proch\u00E1zej\u00ED klinick\u00FDm hodnocen\u00EDm. L\u00E9\u010Diva v r\u00E1mci c\u00EDlen\u00E9 biologick\u00E9 l\u00E9\u010Dby p\u016Fsob\u00ED pouze na tyto molekuly a pochody, zlep\u0161uj\u00ED \u010Di opravuj\u00ED schopnost sebeobrany organismu. Doprov\u00E1z\u00ED je ov\u0161em rovn\u011B\u017E \u0159ada ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F. Nejv\u011Bt\u0161\u00ED p\u0159ek\u00E1\u017Ekou v\u011Bt\u0161\u00EDmu roz\u0161\u00ED\u0159en\u00ED jsou vysok\u00E9 ceny dnes dostupn\u00FDch prepar\u00E1t\u016F. Do pojmu spadaj\u00ED i klasick\u00E9 hum\u00E1nn\u00ED imunologick\u00E9 l\u00E9\u010Div\u00E9 p\u0159\u00EDpravky sest\u00E1vaj\u00EDc\u00ED z vakc\u00EDn, toxin\u016F, s\u00E9r nebo alergenov\u00FDch p\u0159\u00EDpravk\u016F, ale zpravidla se do imunoterapi\u00ED nezahrnuj\u00ED."@cs . . . . "Immunoterapia"@pl . . . . . . . . . . "D007167"@en . "Inmunoterapia"@es . . . "Immunotherapy"@en . "\u0418\u043C\u043C\u0443\u043D\u043E\u0442\u0435\u0440\u0430\u043F\u0438\u044F (\u043B\u0430\u0442. immunis \u2014 \u0441\u0432\u043E\u0431\u043E\u0434\u043D\u044B\u0439, \u0438\u0437\u0431\u0430\u0432\u043B\u0435\u043D\u043D\u044B\u0439 \u043E\u0442 \u0447\u0435\u0433\u043E-\u043B\u0438\u0431\u043E, \u0433\u0440\u0435\u0447., therapeia \u2014 \u043B\u0435\u0447\u0435\u043D\u0438\u0435) \u2014 \u0440\u0430\u0437\u0434\u0435\u043B \u043F\u0440\u0430\u043A\u0442\u0438\u0447\u0435\u0441\u043A\u043E\u0439 \u0438\u043C\u043C\u0443\u043D\u043E\u043B\u043E\u0433\u0438\u0438, \u0437\u0430\u0434\u0430\u0447\u0430 \u043A\u043E\u0442\u043E\u0440\u043E\u0433\u043E \u2014 \u043B\u0435\u0447\u0435\u043D\u0438\u0435 \u0438\u043C\u043C\u0443\u043D\u043E\u043B\u043E\u0433\u0438\u0447\u0435\u0441\u043A\u0438\u043C\u0438 \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442\u0430\u043C\u0438, \u043A\u043E\u0442\u043E\u0440\u044B\u0435 \u0432\u043E\u0437\u0434\u0435\u0439\u0441\u0442\u0432\u0443\u044E\u0442 \u043F\u0440\u0438\u0446\u0435\u043B\u044C\u043D\u043E \u043D\u0430 \u0438\u043C\u043C\u0443\u043D\u043D\u0443\u044E \u0441\u0438\u0441\u0442\u0435\u043C\u0443: \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442\u0430\u043C\u0438 \u0430\u043D\u0442\u0438\u0442\u0435\u043B \u0438\u043B\u0438 \u0441\u044B\u0432\u043E\u0440\u043E\u0442\u043E\u043A, \u043C\u043E\u043D\u043E\u043A\u043B\u043E\u043D\u0430\u043B\u044C\u043D\u044B\u043C\u0438 \u0430\u043D\u0442\u0438\u0442\u0435\u043B\u0430\u043C\u0438, \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442\u0430\u043C\u0438 \u043C\u0438\u043A\u0440\u043E\u0431\u043D\u043E\u0433\u043E \u043F\u0440\u043E\u0438\u0441\u0445\u043E\u0436\u0434\u0435\u043D\u0438\u044F, \u0446\u0438\u0442\u043E\u043A\u0438\u043D\u043E\u0432\u0430\u044F \u0438 \u0430\u043D\u0442\u0438\u0446\u0438\u0442\u043E\u043A\u0438\u043D\u043E\u0432\u0430\u044F \u0442\u0435\u0440\u0430\u043F\u0438\u044F, \u043A\u043B\u0435\u0442\u043E\u0447\u043D\u0430\u044F \u0442\u0435\u0440\u0430\u043F\u0438\u044F. \u0418\u043C\u043C\u0443\u043D\u043E\u0442\u0435\u0440\u0430\u043F\u0438\u044E \u0432 \u043A\u0430\u0447\u0435\u0441\u0442\u0432\u0435 \u0432\u0441\u043F\u043E\u043C\u043E\u0433\u0430\u0442\u0435\u043B\u044C\u043D\u043E\u0433\u043E \u043C\u0435\u0442\u043E\u0434\u0430 \u043F\u0440\u0438\u043C\u0435\u043D\u044F\u044E\u0442 \u043F\u0440\u0438 \u0438\u043D\u0444\u0435\u043A\u0446\u0438\u043E\u043D\u043D\u044B\u0445, \u043E\u043D\u043A\u043E\u043B\u043E\u0433\u0438\u0447\u0435\u0441\u043A\u0438\u0445 \u0437\u0430\u0431\u043E\u043B\u0435\u0432\u0430\u043D\u0438\u044F\u0445, \u0432 \u044D\u0442\u043E\u043C \u0441\u043B\u0443\u0447\u0430\u0435 \u0447\u0430\u0449\u0435 \u0441\u043E\u0447\u0435\u0442\u0430\u044E\u0442 \u0441 \u043B\u0435\u0447\u0435\u043D\u0438\u0435\u043C \u0430\u043D\u0442\u0438\u0431\u0438\u043E\u0442\u0438\u043A\u0430\u043C\u0438 \u0438 \u0445\u0438\u043C\u0438\u043E\u0442\u0435\u0440\u0430\u043F\u0438\u0435\u0439. \u0418\u043C\u043C\u0443\u043D\u043E\u0442\u0435\u0440\u0430\u043F\u0438\u044F \u043F\u043E\u043A\u0430\u0437\u0430\u043D\u0430 \u043F\u0440\u0438 \u043F\u0435\u0440\u0432\u0438\u0447\u043D\u043E\u043C \u043D\u0430\u0440\u0443\u0448\u0435\u043D\u0438\u0438 \u0440\u0430\u0431\u043E\u0442\u044B \u0438\u043C\u043C\u0443\u043D\u043D\u043E\u0439 \u0441\u0438\u0441\u0442\u0435\u043C\u044B \u2014 \u0438\u043C\u043C\u0443\u043D\u043E\u0434\u0435\u0444\u0438\u0446\u0438\u0442\u0430\u0445, \u0430\u0443\u0442\u043E\u0438\u043C\u043C\u0443\u043D\u043D\u044B\u0445 \u0437\u0430\u0431\u043E\u043B\u0435\u0432\u0430\u043D\u0438\u044F\u0445."@ru . "Immunoterapia"@it . . "Imunoterapie"@cs . . . "A imunoterapia \u00E9 um ramo da terapia que cuida do tratamento e imunoprofilaxia de doen\u00E7as infecciosas, al\u00E9rgicas, parasitarias e cancer\u00EDgenas . Usando como meio recursos imunol\u00F3gicos. Experi\u00EAncias com multiplica\u00E7\u00E3o de linf\u00F3citos ativados, retirados da bi\u00F3psia e cultivados, tem tido sucesso em bom percentual de casos de c\u00E2ncer. Esta abordagem explora o fato de que as c\u00E9lulas cancer\u00EDgenas frequentemente possuem mol\u00E9culas em sua superf\u00EDcie que podem ser detectadas pelo sistema imunol\u00F3gico, conhecidas como ant\u00EDgenos tumorais. Uma grande quantidade de c\u00E2nceres humanos tem ant\u00EDgenos incluindo linfoma de Burkitt, neuroblastoma, melanoma maligno, osteossarcoma, carcinoma de c\u00E9lulas renais, cancro de mama, c\u00E2ncer de pr\u00F3stata, c\u00E2nceres pulmonares e c\u00E2ncer de c\u00F3lon. Muitas vezes s\u00E3o prote\u00EDnas ou outras macromol\u00E9culas (por exemplo, carboidratos). As imunoterapias podem ser categorizadas como ativas, passivas ou h\u00EDbridas (ativa e passiva). A imunoterapia ativa direciona o sistema imunol\u00F3gico para atacar as c\u00E9lulas tumorais, visando os TAAs (Tumor Associated Antigens) ou mesmo ant\u00EDgenos espec\u00EDficos de tumores TSAs (Tumor Specific Antigens). As imunoterapias passivas melhoram as respostas antitumorais existentes e incluem o uso de anticorpos monoclonais, linf\u00F3citos e citocinas . Entre elas, v\u00E1rias terapias com anticorpos s\u00E3o aprovadas em v\u00E1rias jurisdi\u00E7\u00F5es para tratar uma ampla gama de c\u00E2nceres. Anticorpos s\u00E3o prote\u00EDnas produzidas pelo sistema imunol\u00F3gico que se ligam a um ant\u00EDgeno alvo na superf\u00EDcie celular. O sistema imunol\u00F3gico normalmente os usa para combater pat\u00F3genos . Cada anticorpo \u00E9 espec\u00EDfico para uma ou algumas prote\u00EDnas. Aqueles que se ligam a ant\u00EDgenos tumorais tratam o c\u00E2ncer. Os receptores de superf\u00EDcie celular s\u00E3o alvos comuns para terapias de anticorpos e incluem CD20 , CD274 e CD279. Uma vez ligado a um ant\u00EDgeno de c\u00E2ncer, os anticorpos podem induzir citotoxicidade mediada por c\u00E9lulas dependente de anticorpos, ativar o sistema complemento ou impedir que um receptor interaja com o seu ligando , o que pode levar \u00E0 morte celular. Anticorpos aprovados incluem alemtuzumab , ipilimumab , , e rituximab. Algumas drogas tem sido administradas com a finalidade da c\u00E9lula cancerosa ser percebida pelo sistema de defesa."@pt . . . "\u0418\u043C\u043C\u0443\u043D\u043E\u0442\u0435\u0440\u0430\u043F\u0438\u044F"@ru . . . . . . . . . . . "Immunoter\u00E0pia"@ca . . .